

















































































This	 thesis	 is	 my	 own	 work	 and	 includes	 nothing	 which	 is	 the	 outcome	 of	 work	 done	 in	
collaboration	 except	 as	 declared	 in	 the	 ‘Contributions	 and	 Collaborations’	 sections	 at	 the	
beginning	of	each	chapter	or	as	specified	in	the	text.		
	
No	 part	 of	 this	 thesis	 is	 substantially	 similar	 to	 any	work	 that	 I	 have	 submitted,	 or,	 is	 being	

































































































Events	 in	 early	 life	 have	 consistently	 been	 associated	with	 health	 outcomes	 in	 later	 life.	 The	




particular,	a	 secular	 trend	 for	a	decreasing	age	of	puberty	onset	has	been	 linked	 to	 the	global	
increases	 in	 prevalence	 of	 cardio-metabolic	 diseases	 and	 cancer.	 It	 has	 been	 suggested	 that	





While	 environmental	 exposures	 are	 often	 cited	 as	 being	 highly	 influential	 on	 growth	 and	
development,	the	role	of	genetics	has	become	gradually	more	apparent	in	recent	years.	This	has	
been	aided	by	the	availability	of	 increasingly	large	data	resources.	Genetic	studies	have	shown	




of	 genetic	 and	 epigenetic	 factors	 in	 explaining	 observed	 associations	 between	 developmental	
traits	and	later	life	metabolic	and	reproductive	health.	I	begin	by	examining	the	genetic	aetiology	
of	puberty	timing	in	men,	a	key	stage	of	sexual	development	which	is	understudied	compared	to	
women.	 I	 identify	 29	 novel	 genes	 involved	 in	 the	 control	 of	 puberty	 timing,	 implicating	 new	
biological	pathways	and	demonstrate	genetic	 correlations	between	earlier	 age	of	puberty	 and	







as	mediating	 factors	 to	 explain	 the	 link	between	earlier	puberty	 and	heightened	 reproductive	
health	risks.	
 6 
I	 go	 on	 to	 examine	 mechanisms	 linking	 early	 life	 markers	 of	 development	 to	 adult	 health.	 I	
investigate	 the	 association	 between	 weight	 at	 birth	 and	 body	 composition	 in	 adulthood,	
determining	 that	 foetal	 and	 maternal-specific	 genetic	 determinants	 of	 birth	 weight	 have	
differential	influences	on	fat	and	lean	mass	distribution.	Downstream	analyses	suggest	that	these	
operate	 through	 distinct	 biological	 pathways,	 adding	 to	 our	 understanding	 of	 the	 association	
between	low	birth	weight	and	poor	health.	Finally,	I	conduct	an	epigenome-wide	association	study	
(EWAS)	 as	 a	 complementary	 approach	 to	 GWAS	 for	 both	 BMI	 and	 puberty	 timing	 to	 identify	
additional	 genomic	 loci	 associated	with	both	 traits.	Using	EWAS	data	 I	present	 evidence	 for	 a	
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significant	 threats	 to	 global	 public	 health.	 In	 2016,	 the	 World	 Health	 Organisation	 (WHO)	
estimated	that	worldwide	39%	of	adults	over	the	age	of	18	years	were	overweight	as	classified	by	
a	 body	 mass	 index	 (BMI)	 greater	 than	 25kg/m2.	 Of	 these,	 13%	 are	 classified	 as	 obese	
(BMI>30kg/m2)1.	 In	the	UK	it	has	been	estimated	that,	among	adults,	65%	of	men	and	58%	of	
women	are	either	overweight	or	obese2.	The	trends	for	the	prevalence	of	obesity	in	childhood	are	
























reproductive	 organs	 and	 tissues,	 pregnancy-related	 outcomes,	 sexually	 transmitted	 infections	
(STIs)	and	violence	against	women.	As	such,	the	most	significant	reproductive	health	issues	are	
likely	 to	 be	 geographically	 varied	 and	population	 specific.	 In	 developing	nations	 a	 substantial	




diseases	 have	 a	 considerably	 greater	 impact	 on	 public	 health.	 For	 example	 polycystic	 ovary	
syndrome	(PCOS),	one	of	the	most	common	chronic	reproductive	health	conditions	in	women,	has	
an	estimated	prevalence	of	5.5%	in	Caucasian	populations12	and	its	treatment	is	estimated	to	cost	
the	 NHS	 over	 £200	million	 annually13.	 Endometriosis,	 another	 common	 chronic	 reproductive	
condition	which	causes	painful	menstruation	and	infertility	in	approximately	1	in	10	women	of	
reproductive	age14,	has	been	estimated	to	have	an	annual	economic	impact	of	over	£8	billion	when	








Figure	 1.1:	 Incidence	 of	 the	 20	 most	 common	 cancer	 types	 in	 the	 United	 Kingdom	 in	 2016.	
















is	 also	 a	 significant	 risk	 factor	 for	 PCOS,	 and	 weight	 reduction	 has	 been	 shown	 to	 improve	
pregnancy	and	general	health	outcomes	in	women	suffering	from	the	condition20,21.	However	the	
relationship	 between	 higher	 BMI	 and	 poor	 reproductive	 health	 is	 not	 consistent	 across	 all	
outcomes,	as	complex	and	condition-specific	associations	have	been	reported.	For	example	there	
is	evidence	that	higher	BMI	is	protective	against	the	risk	of	endometriosis,	though	the	mechanisms	
for	 this	 remain	 unclear22.	 The	 complex	 relationship	 between	 BMI	 and	 reproductive	 health	 is	
further	highlighted	by	cancers	of	the	reproductive	system.	Higher	BMI	has	been	associated	with	
increased	 risk	 of	 ovarian23,24	 and	 endometrial25,26	 cancers	 in	 populations	 of	 diverse	 ancestry.	
Conversely,	 other	 studies	 have	 presented	 evidence	 of	 heterogeneity	 of	 the	 effect	 of	 adiposity	
based	 on	 different	 clinical	 indicators.	 For	 instance	 higher	 BMI	 has	 been	 associated	 with	 a	
decreased	 risk	 of	 breast	 cancer	 in	 pre-menopausal	 women	 while	 increasing	 risk	 after	
menopause27,28.	Similarly,	certain	subtypes	of	ovarian	cancer	have	shown	differential	risks	related	






Over	 the	 past	 decade,	 the	 role	 of	 genetic	 factors	 in	 complex	 disease	 aetiology	 has	 become	
increasingly	 clear.	 This	 has	 been	 made	 possible	 by	 the	 widespread	 use	 of	 genome-wide	
association	studies	(GWAS),	which	have	demonstrated	the	association	between	common	genetic	
variation	 in	 the	 population	 and	 disease	 risk30.	 What	 began	 with	 studies	 of	 a	 few	 thousand	
individuals	genotyped	on	sparse	arrays,	capturing	small	fractions	of	the	totality	of	genetic	variants	
within	the	genome,	has	expanded	dramatically.	This	has	been	enabled	by	large-scale	population	
studies	 and	 increasingly	 efficient	 and	 cost-effective	 high-throughput	 DNA	 sequencing	
technologies30.	 Studies	 such	 as	 the	 UK	 Biobank	 cohort,	 which	 has	 collected	 comprehensive	
phenotype	information	and	conducted	genome-wide	DNA	sequencing	and	imputation	of	genetic	




sources	 in	 large	 consortia,	 recent	 GWAS	 have	 obtained	 sample	 sizes	 in	 excess	 of	 1	 million	
participants33,34,	 providing	 statistical	 power	 to	 identify	 associations	 of	 small	 effect	 with	 great	







Large-scale	 GWAS	 have	 been	 conducted	 for	 several	 reproductive	 health	 traits	 of	 interest,	
identifying	 hundreds	 of	 associated	 genetic	 variants	 which	 have	 contributed	 to	 a	 deeper	
understanding	 of	 the	 biology	 of	 reproduction	 and	 reproductive	 disease.	 Among	 the	 best	
characterised	traits	are	the	timings	of	reproductive	events	including	menarche	and	menopause,	
where	GWAS	have	identified	389	and	106	associated	genetic	loci,	respectively35,36.	Downstream	








Trait	 Study	 Sample	Size	 Associated	
Variants	
Age	at	menarche	 Day	et	al.	(2017)35	 368,888	(European)	 389	
Age	at	menopause	 Perry	et	al.	(2014)36	 182,416	(European)	 106	
Endometriosis	 Sapkota	et	al.	(2017)40	 208,641	(European)	 14	
















techniques	 to	 make	 causal	 inferences	 about	 the	 effects	 of	 exposures	 on	 health	 outcomes.	
Mendelian	 randomisation	 (MR)	 analyses	 are	 based	 on	 the	 principle	 that	 alleles	 segregate	
randomly	and	independently	to	gametes	during	meiosis	(i.e.,	Mendel’s	first	and	second	laws	of	
 27 














1980s,	 based	 on	 work	 from	 David	 Barker	 and	 colleagues	 which	 found	 a	 strong	 correlation	
between	temporal	and	geographic	rates	of	infant	mortality	and	ischemic	heart	disease46.	These	
associations	lead	to	the	development	of	the	‘Foetal	Origins	of	Disease’	theory	which	postulated	









The	 Foetal	 Origins	 theory	 has	 since	 evolved	 to	 incorporate	 developmental	 exposures	 more	














a	 group	 of	 covalent	modifications	 to	 the	 structure	 of	 DNA	which	 do	 not	 alter	 the	 underlying	
sequence	 of	 bases	 which	 make	 up	 the	 genetic	 code.	 Among	 these	 modifications	 are	 DNA	












and	 has	 been	 shown	 to	 be	 ancestry-specific.	 The	 range	 for	 ‘normal’	 birth	 weight	 is	 typically	
considered	to	be	between	2500g	and	4000g	in	individuals	of	European	ancestry,	while	lower	cut-






















Figure	 1.2:	 Centiles	 of	 weight	 for	 gestational	 age	 of	 male	 singletons	 in	 a	 European-ancestry	
















































and	 its	 progress	 is	 often	measured	 by	 distinct	 physiological	markers.	 The	 onset	 of	 puberty	 is	
triggered	 by	 re-activation	 of	 the	 hypothalamic-pituitary-gonadal	 (HPG)	 axis,	 which	 enters	 a	
period	 of	 quiescence	 after	 early	 activity	 in	 the	 post-natal	 period74.	 Stimulation	 of	 increased	
oestrogen	secretion	(in	females)	and	testosterone	secretion	(in	males)	leads	to	the	development	







and	 in	 a	 characteristic	 temporal	 pattern.	 Marshall	 and	 Tanner	 first	 described	 the	 typical	
presentation	of	pubertal	changes,	and	the	Tanner	scale	which	they	developed	is	regularly	used	to	
chart	progression	through	pubertal	development75,76.	The	age	at	which	puberty	 is	said	to	have	




of	detail	 is	not	often	possible	 to	replicate	however,	particularly	 in	 large	biobank-sized	cohorts	














in	 recent	 years	 the	 lowering	 age	 at	puberty	 is	 linked	 to	 an	 increased	prevalence	of	 childhood	
obesity85,86.	The	trend	for	earlier	age	at	puberty	 is	of	concern	for	public	health,	as	puberty	has	
consistently	been	associated	with	risks	for	adverse	health	outcomes87.	Several	hypotheses	have	







Early	 genetic	 studies	 identified	 several	 rare	 variants	 which	 are	 associated	 with	 Mendelian	
disorders	 of	 puberty,	 and	 included	 mutations	 at	 the	MKRN3	 and	 KISS1/KISS1R	 loci	 causing	
precocious	puberty88.	GWAS	have	greatly	expanded	our	knowledge	of	the	genetic	determinants	of
 32 
puberty,	 with	 the	 most	 recent	 study	 on	 AAM	 revealing	 a	 highly	 heritable	 and	 polygenic	
architecture	with	389	associated	genomic	loci35.	Studies	in	men	have	been	far	less	insightful,	as	
the	 largest	male-specific	study	to	date	 identified	only	14	associated	 loci78.	Genetic	correlations	
reveal	 a	 strong	 shared	 genetic	 architecture	 between	 puberty	 timing	 in	 men	 and	 women,	
suggesting	 that	 the	 large	discrepancy	between	 the	number	of	 associated	 loci	 is	 largely	due	 to	







and	much	evidence	has	been	generated	 in	 support	of	 the	DOHaD	hypothesis	 since	 it	was	 first	
proposed.	Much	remains	unknown	however,	particularly	regarding	the	aetiological	mechanisms	












Through	 the	 application	 of	 genetic	 methods,	 this	 thesis	 aims	 to	 address	 these	 questions,	



































































































































completion	 of	 an	 online	 touchscreen	 questionnaire,	 a	 face-to-face	 interview	 and	 collection	 of	
physical	measurements	and	biological	samples.	The	touchscreen	questionnaire	was	designed	to	
collect	 information	 on	 current	 and	 past	 health,	 lifestyle	 health	 exposures	 (e.g.	 diet,	 smoking,	
alcohol	consumption	and	physical	activity),	socioeconomic	factors,	psychological	well-being	and	
cognitive	function.	This	was	followed	by	a	computer-assisted	interview	with	a	trained	nurse	to	



















and	 non-smoking	 UK	 Biobank	 participants93.	 The	 remaining	 participants	 (N=438,427)	 were	
genotyped	at	825,927	markers	using	the	UK	Biobank	Axiom	Array	from	Affymetrix.	These	two	
arrays	 share	 95%	 of	 the	 same	 markers94.	 Genotyping	 was	 conducted	 in	 106	 batches	 of	
approximately	 4700	 samples	 per	 batch,	 resulting	 in	 genotype	 information	 on	 489,212	
participants	 at	 812,428	 bi-allelic	 SNPs	 and	 insertions/deletion	 (indels).	 Poor	 quality	markers	




Markers	 present	 on	 both	 genotyping	 arrays	 were	 taken	 forward	 for	 haplotype	 imputation.	
Markers	that	failed	QC	in	multiple	batches,	had	a	missing	rate	>5%	or	a	MAF<0.0001	were	also
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removed.	 Phasing	 was	 then	 conducted	 on	 autosomes	 using	 SHAPEIT3	 software95	 and	 1000	
Genomes	phase	3	as	 the	reference	panel96.	 Imputation	of	haplotypes	was	performed	using	 the	











investigate	 the	 genetic	 and	 lifestyle	 influences	 on	 cardio-metabolic	 disease100.	 Eligible	
participants	were	 anyone	 born	 between	 1950	 and	 1975	 and	 registered	with	 a	 GP	 practice	 in	
Cambridge	 at	 the	 time	 of	 recruitment.	 Between	 2004	 and	 2014,	 12,242	 participants	 were	
recruited,	with	 an	 overall	 response	 rate	 of	 27%.	 Exclusion	 criteria	were:	 clinical	 diagnosis	 of	
diabetes	mellitus,	inability	to	walk	without	assistance,	terminal	illness	(≤1	year	life	expectancy),	
clinical	diagnosis	of	psychiatric	disorder,	and	current	pregnancy	or	breastfeeding.	Participants	
























over	 500,000	 individuals	 in	multiple	 centres	 throughout	western	 Europe	 and	 Scandanavia102.	
Primarily	designed	to	investigate	the	role	of	diet	in	the	development	of	cancer,	the	cohort	collects	
data	on	multiple	exposures	and	outcomes	allowing	 for	 the	 investigation	of	environmental	and	
genetic	 influences	 on	 chronic	 disease	 risk.	 EPIC-Norfolk	 is	 one	 of	 two	 UK-based	 sub-cohorts,	









(3HC)	and	20	(4HC)	years	after	 initial	assessment	where	 further	data	was	collected,	 including	






DNA	 obtained	 from	 blood	 samples	 was	 extracted	 using	 standard	 protocols.	 Genome-wide	
genotyping	was	performed	using	the	Affymetrix	UK	Biobank	Axiom	array	and	imputed	using	a	







23andMe	 (Mountain	 View,	 CA,	 USA)	 is	 a	 personal	 genomics	 company	 providing	 direct-to-














For	 the	 analyses	 in	 this	 thesis,	 imputation	 was	 performed	 using	 the	 1000	 Genomes	 phase	 3	
reference	panel	after	exclusion	of	SNPs	with	Hardy-Weinberg	equilibrium	(P	<	10-20),	a	call	rate	


































these	methods	 are	 not	 fully	 robust	 to	 fine-scale	 population	 structure	 and	 genetic	 relatedness	
among	 participants.	 Linear	 mixed	 models	 (LMMs)	 are	 now	 predominantly	 used	 in	 genetic	
discovery	in	order	to	explicitly	control	for	population	stratification	and	cryptic	relatedness.	For	







and	 standard	 errors	 are	 obtained	 from	 the	 linear	 regression	 estimates	 using	 the	 following	
formulae:	
	
log$% = 	(/(+ × (1 − +))		 [1]	
	





Combination	 of	 GWAS	 summary	 statistics	was	 performed	 using	 fixed-effects	 inverse-variance	








variants,	 estimates	 were	 obtained	 based	 on	 reference	 values	 from	 1000	 Genomes	 Phase	 3	
European	samples,	implemented	in	LD	Link	(versions	3.2	to	3.7.2)110.	In	addition,	regional	
 41 








defined	 biological	 pathways.	 In	 this	 thesis,	 Meta-Analysis	 Gene	 set	 ENrichment	 of	 varianT	
Associations	 (MAGENTA	 v2.4)112	 was	 used	 to	 assess	 enrichment	 based	 on	 GWAS	 summary	















can	 be	 applied	 to	 genome-wide	 summary	 statistics	 to	 distinguish	 polygenic	 effects	 from	
confounding	factors	such	as	population	stratification.	This	is	achieved	by	computing	population-














reverse	 causation	 and	 confounding,	which	 provide	 a	 significant	 barrier	 to	 casual	 inference	 in	
traditional	epidemiological	studies.	The	idea	is	based	on	(and	named	after)	Mendel’s	first	two	laws	




by	Davey-Smith	and	Ebrahim45,	 and	since	 the	advent	of	GWAS	 it	has	been	used	extensively	 in	
genetic	epidemiology	as	a	tool	for	making	causal	inference.	Many	extensions	of	the	method	have	









the	 outcome.	 Primary	 MR	 analyses	 employ	 the	 inverse-variance	 weighted	 (IVW)	 regression	































balanced	(i.e.	 they	do	not	sum	to	zero	–	so	called	 ‘directional	pleiotropy’)	 then	the	second	MR	
assumption	is	violated	and	the	causal	estimate	from	the	IVW	method	may	be	biased	away	from	
the	null118.	To	mitigate	these	effects,	MR-Egger	regression	is	applied	as	a	sensitivity	analysis	to	
test	 for	 the	presence	of	 directional	 pleiotropy	which	may	bias	 the	 results	 of	MR119.	MR-Egger	
allows	for	the	possibility	of	multiple	invalid	instruments	by	not	forcing	the	regression	line	to	pass	
through	the	origin.	While	MR-Egger	has	been	shown	to	be	generally	underpowered	compared	to	



















































































Inc.,	 Mountain	 View,	 CA);	 replication	 of	 signals	 using	 the	 genetic	 risk	 scores	 in	 ALSPAC	 was	







































represents	 a	 nearly	 four-fold	 increase	 from	 the	 largest	 previously	 reported.	 76	 independent	


















































The	 triggers	 for	puberty	onset	 are	an	area	of	 intense	 scientific	 interest.	Puberty	 timing	varies	










timing	 has	 been	 shown	 to	 increase	 the	 risk	 of	 many	 cancers,	 cardiovascular	 and	 metabolic	
conditions,	 as	 well	 as	 gynaecological,	 gastrointestinal	 and	 musculoskeletal	 disorders87.	 It	 is	
therefore	of	importance	to	understand	the	aetiology	and	mechanisms	controlling	pubertal	onset,	












set	enrichment	 in	 retinoic	pathways	 (among	others),	 and	provided	 robust	evidence	 for	 causal	
links	between	early	puberty	and	poor	adult	health,	corroborating	observational	evidence.		
	
Large-scale	 genetic	 studies	 on	 puberty	 timing	 conducted	 to	 date	 have	 primarily	 focused	 on	
women,	 due	 to	 the	 fact	 that	 AAM	 is	 often	 a	more	memorable	 and	 easily	 recalled	marker	 for	
puberty	 timing	 than	 male	 pubertal	 milestones,	 and	 is	 therefore	 regularly	 recorded	 in	 large	
cohorts.	 The	 largest	male-specific	 study	on	puberty	 genetics	was	 conducted	 in	 a	 considerably	
smaller	sample	of	~55,000	men	and	used	recalled	age	of	voice	breaking	as	a	marker	for	puberty	
onset78.	The	study	identified	14	independently	associated	signals	 for	male	puberty	timing,	and	
individual	 effect	 sizes	 were	 strongly	 correlated	 with	 AAM	 effects	 (rg=0.74),	 providing	 strong	
support	for	voice	breaking	as	a	valid	maker	for	puberty.		
	









The	 lack	 of	 large-scale	 genetic	 studies	 for	 puberty	 timing	 in	men,	 along	with	 the	 examples	 of	
variants	 with	 sex-specific	 effects,	 highlights	 the	 need	 for	 further	 research	 into	 male	 puberty	




incorporates	 this	 information	 with	 the	 previously	 analysed	 data	 on	 voice	 breaking	 from	 the	
23andMe	study,	employing	a	method	which	allows	for	meta-analysis	of	related	traits	from	
 50 

















































questions	 “When	 did	 your	 voice	 break?”	 and	 “When	 did	 you	 start	 to	 grow	 facial	 hair?”,	







Details	 on	 genotyping	 and	 imputation	methods	 for	 the	 23andMe	 and	UK	Biobank	 studies	 are	
described	in	Chapter	2.	In	the	23andMe	study,	genetic	and	phenotypic	data	were	available	in	up	
to	55,871	unrelated	men	across	13.7	million	imputed	variants.	Genetic	associations	with	age	at	






analysis,	 we	 restricted	 our	 sample	 to	 unrelated	 individuals	 of	 self-reported	 white	 European	
ancestry.	Respondents	who	answered	either	 ‘older	than	average’	or	 ‘younger	than	average’	for	
each	 phenotype	were	 compared	 in	 separate	models	 using	 logistic	 regression,	with	 the	 ‘about	











by	 Turley	 et	 al.140.	 MTAG	 uses	 GWAS	 summary	 statistics	 from	 multiple	 correlated	 traits	 to	
effectively	increase	sample	size	and	statistical	power	to	detect	genetic	associations,	by	estimating	
a	variance-covariance	matrix	 to	 correlate	 the	effect	 sizes	of	 each	 trait	using	a	moments-based	
method.	In	addition,	MTAG	calculates	a	variance-covariance	matrix	for	the	GWAS	estimation	error	
using	 LD	 score	 regressions.	 SNP	 effect	 estimates	 are	 then	 calculated	 for	 each	 trait	 using	 a	











bound	 for	 the	 false	 discovery	 rate	 (maxFDR)	 was	 calculated,	 as	 recommended	 by	 the	 MTAG	
authors.	Prior	 to	meta-analysis,	we	removed	rare	variants	(MAF<0.01).	 In	addition,	due	 to	 the	




















SNP	 associations.	 Independent	 signals	 were	 identified	 using	 a	 combination	 of	 distance-based	





there	were	no	previously	reported	puberty	 loci	 (for	either	AAM	or	VB)	within	1	MB,	or	 if	any	
previously	 reported	 loci	 within	 1	MB	were	 not	 in	 LD	with	 it	 (r2<0.05).	 Gene	 annotation	was	
performed	using	a	combination	of	methods.	Information	on	the	nearest	gene,	as	well	as	all	non-









was	 sought	 in	 an	 independent	 cohort.	 The	 Avon	 Longitudinal	 Study	 of	 Parents	 and	 Children	




details	 of	 recruitment,	 follow-up	 and	 data	 collection	 have	 been	 reported	 previously.	 Ethical	
approval	for	the	study	was	obtained	from	the	ALSPAC	Ethics	and	Law	committee	and	the	Local	
Research	 Ethics	 Committees.	 A	 series	 of	 nine	 postal	 questionnaires	 regarding	 pubertal	
development	were	administered	annually	from	the	time	the	participant	was	aged	8	until	the	age	
of	17.	The	questionnaires,	which	were	responded	to	by	either	the	parents	or	the	participant,	had	
schematic	drawings	and	verbal	descriptions	of	 secondary	 sexual	 characteristics	 (genitalia	 and	
pubic	hair	development)	based	on	the	Tanner	staging	system,	as	well	as	information	on	armpit	
hair	growth	and	voice	change.	Age	at	voice	change	was	considered	the	age	at	which	the	adolescent	
reported	his	voice	 to	be	“occasionally	a	 lot	 lower	or	 to	have	changed	completely”.	Weight	and	
height	were	measured	annually	up	 to	age	13	years,	 then	at	ages	15	and	17	years	by	a	 trained	




GWAS,	weighted	by	 the	effect	size	 for	 that	SNP	as	reported	 in	 the	ReproGen	Consortium	AAM	
GWAS.	The	GRS	was	standardised,	and	results	presented	are	the	increase	in	the	phenotype	per	








were	 obtained	 from	AAM	GWAS	data	 from	 the	ReproGen	 consortium35.	 In	 addition,	 summary	















Genome-wide	meta-analysis	 summary	statistics	 for	male	puberty	 timing	were	 investigated	 for	
gene-set	enrichment	in	known	biological	pathways	using	MAGENTA112.	Testing	was	performed	on	






LD	 score	 regression113	 was	 used	 to	 determine	 genetic	 correlations	 (rg)	 using	 meta-analysis	































were	unrelated	and	of	white	European	descent.	Hazard	 ratios	and	 their	 standard	errors	were	
taken	forward	for	74	male	puberty	loci	which	were	available	in	this	dataset,	and	two-sample	MR	











your	 natural	 hair	 colour?	 (If	 your	 hair	 colour	 is	 grey,	 the	 colour	 before	 you	 went	 grey)”.	
Participants	chose	from	one	of	6	possible	colours:	blond,	red,	light	brown,	dark	brown,	black	or	
other.	 For	 our	 analyses,	 we	 restricted	 this	 to	 include	 only	 non-related	 individuals	 of	 white	
European	 ancestry,	 totalling	 190,845	 men	 and	 238,179	 women.	 Hair	 colours	 were	 assigned	










puberty	 timing,	 two-sample	 MR	 analysis	 was	 performed.	 Summary	 statistics	 for	 natural	 hair	
colour	were	obtained	from	publicly	available	data	from	a	recently	published	GWAS145.	Summary	








colour	 GWAS,	which	 both	 included	 23andMe	 participants,	 we	 performed	 a	 further	 sensitivity	
analysis	in	non-overlapping	samples.	This	consisted	of	a	more	limited	5-SNP	instrument	that	did	
not	include	data	from	23andMe	or	UK	Biobank105.	This	was	then	assessed	for	effects	on	puberty	
































relatively	 late	 facial	 hair.	 This	 represents	 a	 significantly	 higher	 proportion	 than	 expected	 by	

























5,952	 6,254	 125	 12,331	
About	average	
age	
1,980	 150,303	 1,832	 154,115	
Older	than	
average	
236	 14,180	 9,300	 23,716	












output	using	LD	 score	 regression,	were	high	 (rg	 ranging	 from	0.57	and	0.91).	A	 total	 of	7,897	
variants	 were	 associated	 with	 male	 puberty	 timing	 at	 genome-wide	 statistical	 significance	
(P<5×10-8),	comprising	76	independent	signals	(Figure	3.1).	The	maxFDR	calculation	from	MTAG	
was	 7.9×10-4,	 indicating	 that	 test	 statistics	 are	 unlikely	 to	 be	 biased	 due	 to	 violation	 of	 the	
homogeneity	assumption.	The	most	significantly	associated	variant	 (rs11156429,	P=3.5×10-52)	
was	located	in/near	LIN28B,	consistent	with	previously	reported	studies	in	men	and	women35,78.	
Associations	with	voice	breaking	 loci	at	 the	NR4A2	 (P=8.6×10-36),	TMEM38B	 (P=1.3×10-32)	and	
LEPR	 (P=6.1×10-22)	 loci	were	 also	 replicated	 in	 this	 analysis78.	 Of	 the	 76	 signals,	 29	were	 not	
within	 1	MB	 or	 in	 linkage	 disequilibrium	 (r2>0.05)	with	 a	 previously	 reported	 AAM	 or	 voice	
breaking	 SNP	 and	were	 therefore	 considered	 novel	 (Table	 3.2).	 Two	 of	 the	 76	 lead	 variants	
associated	with	male	pubertal	timing	were	non-synonymous:	a	previously	reported	AAM	signal	
in	KDM4C	(rs913588),	encoding	a	lysine-specific	demethylase,	and	a	novel	male-specific	signal	in	









variants	 are	 in	 the	 following	 genes:	 SRD5A2,	 encoding	 for	 Steroid	 5-alpha-reductase,	 which	
converts	testosterone	into	the	more	potent	androgen	dihydrotestosterone;	LEPR,	encoding	the	













Variant	 Chr	 Position	 Alleles#	 EAF	 Nearest	gene	 MTAG		Beta	(S.E.)	
MTAG	
P-value	
rs71578952	 7	 131,001,466	 C/T	 0.495	 MKLN1	 0.035	(0.003)	 8.4×10-28	
rs2222746	 17	 44,222,019	 T/G	 0.165	 KIAA1267	 0.048	(0.004)	 9.0×10-28	
rs73182377	 3	 181,512,034	 C/T	 0.227	 SOX2OT	 0.040	(0.004)	 1.9×10-24	
rs3824915	 11	 44,331,509	 G/C	 0.496	 ALX4	 0.030	(0.003)	 1.0×10-20	
rs77578010	 1	 11,035,758	 A/G	 0.776	 C1orf127	 0.036	(0.004)	 1.1×10-20	
rs7402990	 15	 28,384,491	 G/A	 0.916	 HERC2	 0.051	(0.006)	 1.4×10-18	
rs17833789	 17	 55,230,628	 C/A	 0.547	 AKAP1	 0.028	(0.003)	 5.9×10-18	
rs12203592	 6	 396,321	 C/T	 0.170	 IRF4	 0.035	(0.004)	 9.6×10-16	
rs35063026	 16	 89,736,157	 T/C	 0.069	 C16orf55	 0.051	(0.006)	 2.1×10-15	
rs9690350	 7	 547,800	 C/G	 0.419	 PDGFA	 0.025	(0.003)	 3.2×10-14	
rs6560353	 9	 76,375,544	 G/T	 0.161	 ANXA1	 0.033	(0.004)	 9.7×10-14	
rs7905367	 10	 54,334,653	 G/C	 0.219	 MBL2	 0.027	(0.004)	 4.7×10-12	
rs7136086	 12	 114,129,719	 C/T	 0.734	 RBM19	 0.025	(0.004)	 1.4×10-11	
rs10110581	 8	 60,691,207	 G/A	 0.263	 CA8	 0.025	(0.004)	 2.3×10-11	
rs2842385	 6	 19,078,274	 G/A	 0.193	 MIR548A1	 0.027	(0.004)	 2.5×10-11	
rs11836880	 12	 91,243,529	 C/G	 0.040	 C12orf37	 0.053	(0.008)	 1.1×10-10	
rs10164550	 2	 121,159,205	 A/G	 0.657	 INHBB	 0.022	(0.003)	 1.7×10-10	
rs12895406	 14	 36,998,950	 A/G	 0.536	 NKX2-1	 0.021	(0.003)	 2.8×10-10	
rs835648	 3	 136,671,504	 A/T	 0.696	 NCK1	 0.022	(0.004)	 5.2×10-10	
rs780094	 2	 27,741,237	 T/C	 0.413	 GCKR	 0.020	(0.003)	 7.8×10-10	
rs1979835	 5	 135,689,839	 A/G	 0.876	 TRPC7	 0.029	(0.005)	 2.5×10-9	
rs12930815	 16	 4,348,635	 C/T	 0.521	 TFAP4	 0.019	(0.003)	 2.6×10-9	
rs12940636	 17	 53,400,110	 C/T	 0.655	 HLF	 0.020	(0.003)	 3.6×10-9	
rs60856990	 17	 7,337,853	 A/G	 0.629	 TMEM102	 0.019	(0.003)	 1.3×10-8	
rs17193410	 17	 32,474,149	 G/A	 0.880	 ACCN1	 0.028	(0.005)	 1.5×10-8	
rs11761054	 7	 46,076,649	 G/C	 0.291	 IGFBP3	 0.020	(0.004)	 2.2×10-8	
rs10765711	 11	 94,879,318	 C/G	 0.415	 ENDOD1	 0.018	(0.003)	 2.9×10-8	
rs61168554	 15	 99,286,980	 A/G	 0.361	 IGF1R	 0.019	(0.003)	 3.8×10-8	







































































Phenotype	 Mean	Age	 N	 Beta	 SE	 P-value	 r
2	(%)	
Age-combined	variables†	 	 	 	 	 	 	
Age	at	peak	height	velocity	(years)	 -	 2,028	 0.157	 0.020	 1.6×10-14	 3.3	
Age	at	voice	break	(years)	 -	 2,343	 0.101	 0.036	 4.5×10-3	 0.6	
Age	of	armpit	hair	appearance	
(years)	 -	 2,403	 0.120	 0.030	 7.3×10-5	 1.1	
	 	 	 	 	 	 	
Age-specific	variables	 	 	 	 	 	 	
Tanner	stage	of	genital	
development	 9.6	 2,191	 -0.009	 0.039	 0.82	 0.4	
Tanner	stage	of	pubic	hair	
development	 9.6	 2,139	 -0.028	 0.057	 0.62	 0.7	
Voice	break	(Y/N)	 9.6	 2,280	 0.014	 0.103	 0.89	 1.0	
	 	 	 	 	 	 	
Tanner	stage	of	genital	
development	 13.1	 1,555	 -0.240	 0.047	 2.4×10-7	 0.9	
Tanner	stage	of	pubic	hair	
development	 13.1	 1,749	 -0.260	 0.042	 7.5×10-10	 1.0	
Voice	break	(Y/N)	 13.1	 1,886	 -0.247	 0.047	 1.4×10-7	 1.6	
Appearance	of	armpit	hair	 13.1	 1,861	 -0.197	 0.048	 4.3×10-5	 1.4	
	 	 	 	 	 	 	
Tanner	stage	of	genital	
development	 17.0	 1,127	 -0.214	 0.067	 1.3×10-3	 1.3	
Tanner	stage	of	pubic	hair	
development	 17.0	 1,268	 -0.269	 0.071	 1.6×10-4	 1.7	
Voice	break	(Y/N)	 17.0	 1,143	 0.161	 0.070	 0.02	 1.4	
Appearance	of	armpit	hair	 17.0	 1,274	 -0.063	 0.199	 0.75	 7.5	





Consistent	with	previous	 studies35,	 a	moderately	 strong	 genome-wide	 genetic	 correlation	was	
observed	 between	 pubertal	 timing	 in	 men	 and	 women	 (rg=0.68,	 P=2.6×10-213)	 (Figure	 3.2).		
However	there	were	exceptions	to	this	overall	trend,	with	5	of	76	male	puberty	signals	and	15	of	
387	AAM	signals	showing	significant	heterogeneity	in	their	effects	between	sexes.	As	previously	
reported35,	 one	 signal	at	 the	SIM1/PRDM13/MCHR2	 locus	 showed	significant	and	directionally	
opposite	effects	where	the	allele	that	conferred	earlier	puberty	timing	 in	men	delayed	AAM	in	
women	 (rs6931884/T:	 βvoice-breaking=	 -0.064	 years/allele;	 βmenarche=0.059	 years/allele;	
Pheterogeneity=2.6×10-14).	Two	variants	located	near	to	genes	that	are	disrupted	in	rare	disorders	of	
puberty	 showed	 no	 effect	 or	weaker	 effect	 in	males	 than	 in	 females:	 rs184950120,	 5’UTR	 to	
MKRN3	 (βvoice-breaking=0.085	 years/allele;	 βmenarche=0.396	 years/allele,	 Pheterogeneity=3.6×10-3),	 and	










































































Gene	 expression	 analysis	 for	 general	 tissue	 categories	 in	GTEx	 indicated	 that	 central	 nervous	
system	(CNS)	 tissues	were	 the	most	 strongly	enriched	 for	genes	which	co-locate	near	 to	male	
puberty	 timing	 signals	 (enrichment	 P=4.4×10-8).	 Significant	 enrichment	 was	 also	 found	 for	
adrenal	 and	 pancreas	 tissues	 (P=3.2×10-6),	 skeletal	muscle	 (P=1.2×10-4),	 connective	 and	 bone	
tissue	 (P=4.7×10-4)	 as	 well	 as	 liver	 (P=1.4×103)	 and	 kidney	 (P=4.3×10-3)	 (Figure	 3.3).	When	
specific	 tissues	 were	 considered,	 none	 of	 the	 53	 GTEx	 tissues	 analysed	 showed	 statistically	
significant	 enrichment	 after	 applying	 a	 Bonferroni	 correction	 to	 account	 for	 multiple	 tests.	
Strongest	 enrichment	 occurred	 in	 the	 cerebellar	 hemisphere	 (P=6.9×10-3),	 cerebral	 cortex	




















































































































































































































































































































































































































































































































correlations	 with	 adolescent	 growth	 (rg=0.77)	 and	 AAM	 (rg=0.68).	 Additionally,	 later	 male	
puberty	was	positively	correlated	with	social	and	behaviour	traits	including	age	at	first	live	birth	
(rg=0.26),	 attainment	 of	 university-level	 degree	 (rg=0.18)	 and	 fluid	 intelligence	 (rg=0.13).	
Furthermore,	 overall	 health	 rating	 showed	 strong	 positive	 correlation	 with	 later	 puberty	
(rg=0.22)	 (Figure	3.5).	 In	 contrast,	 the	 data	 suggest	 that	 individuals	who	 go	 through	puberty	
earlier	are	at	increased	risk	for	a	number	of	adverse	health	outcomes	in	later	life	based	on	negative	
genetic	 correlations,	 including	 hypertension	 (rg=-0.16),	 diabetes	 (rg=-0.22)	 and	 osteoarthritis	































of	genetically-predicted	BMI	as	a	 covariate.	 In	 two-sample,	multivariate	approach	a	protective	
effect	for	later	puberty	timing	on	prostate	cancer	was	observed	when	adjusting	for	BMI,	however	
-0.40 -0.20 0.00 0.20 0.40 0.60 0.80 1.00
Body mass index (BMI)
Pain all over the body










Number of non-cancer illnesses
Back pain
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all	 cases;	 OR=0.82,	 P=0.05	 for	 advanced	 cases)	 (Table	 3.4).	 Similarly,	 higher	 BMI	 shows	







In	 contrast,	 strong	 evidence	was	 found	 for	 a	 causal	 effect	 of	male	puberty	 timing	on	 lifespan,	
corresponding	to	~9	months	 longer	 life	per	year	 later	puberty	(IVW	P=6.7×10-4)	(Figure	3.6).	
This	result	was	consistent	after	removal	of	one	outlier	SNP	using	MR-PRESSO	(P=8.3×10-4)	while	







	 Odds	Ratio	 95%	CI	 P-value	 I2	(%)	 Phet	 MR	Egger	(P-value)	
All	prostate	cancers	 	 	 	 	 	 	
Puberty	timing	 0.94	 0.84-1.05	 0.27	 48.0	 2.7×10-6	 0.20	
Puberty	timing	(adj.	BMI)	 0.89	 0.79-1.01	 0.06	 46.4	 8.2×10-6	 0.10	
BMI	 0.90	 0.81-1.00	 0.06	 49.3	 4.5×10-8	 0.36	
	 	 	 	 	 	 	
Advanced	prostate	
cancers	
	 	 	 	 	 	
Puberty	timing	 0.87	 0.72-1.05	 0.13	 30.7	 0.01	 0.02	
Puberty	timing	(adj.	BMI)	 0.82	 0.68-1.00	 0.05	 29.3	 0.01	 0.01	




















Gene	annotation	of	 the	76	 independent	 loci	 for	male	puberty	 timing	 revealed	 three	novel	 loci	
which	were	located	nearby	to	genes	previously	associated	with	pigmentation:	HERC2,	IRF4,	and	



















colour	 Effect	 95%	CI	 P-value	 Effect	 95%	CI	 P-value	
Blond	 (ref)	 	 	 (ref)	 	 	
Red	 1.17	 1.02,	1.35	 0.02	 -0.100	 -0.134,	-0.066	 6.2×10-9	
Light	brown	 1.00	 0.91,	1.09	 0.92	 -0.026	 -0.047,	-0.005	 0.01	
Dark	brown	 1.45	 1.34,	1.58	 6.7×10-18	 -0.093	 -0.144,	-0.072	 6.7×10-18	





timing	 in	 a	 two-sample	 MR	 approach.	 In	 contrast	 to	 more	 typical	 application	 of	 MR	 to	 infer	
causality	between	an	exposure	and	an	outcome,	 in	this	setting	the	approach	can	provide	more	
explicit	 evidence	 of	 shared	 biological	mechanisms	 linking	 these	 traits.	 The	 findings	 from	 this	
analysis	are	 largely	 in	 line	with	 the	phenotypic	observations,	as	 IVW	MR	in	men	suggests	 that	
darker	natural	hair	colour	is	associated	with	earlier	puberty	timing	in	men	(β=	-0.044	years	per	
ordered	 category,	 P=7×10-3)	 (Figure	 3.7).	 Cochrane’s	 Q	 statistic	 show	 no	 evidence	 for	




















   
Figure	3.7:	Mendelian	randomisation	analyses	for	effect	of	hair	pigmentation	on	puberty	timing	in	men	and	women.	SNP	effect	size	on	hair	colour	is	
plotted	on	the	x-axis,	while	corresponding	effect	on	age	at	voice	breaking	in	men	(left	panel)	and	age	at	menarche	in	women	(right	panel)	is	plotted	on	the	y-















This	 multi-trait	 meta-analysis,	 which	 incorporates	 phenotypes	 from	 the	 UK	 Biobank	 and	
23andMe	 studies	 in	 an	 effective	 sample	 of	 205,354	 men,	 identified	 76	 independent	 loci	 for	
puberty	timing	in	men	of	which	29	had	not	previously	been	associated	with	puberty	in	either	sex.	
These	novel	loci	implicate	genes	with	known	links	to	endocrine	function,	such	as	the	INHBB	gene	
which	 encodes	 the	 beta-B	 subunit	 of	 the	 Inhibin	 B	 hormone	 and	 influences	 the	 onset	 of	
spermatogenesis	by	 inhibiting	 follicle	 stimulating	hormone	 (FSH)	 secretion.	 Similarly,	SRD5A2	
which	 encodes	 the	 steroid	 hormone	 5-alpha-reductase	 is	 responsible	 for	 the	 conversion	 of	
testosterone	to	dihydrotestosterone,	is	essential	for	development	of	secondary	sex	characteristics	
associated	 with	 puberty.	 Genome-wide	 expression	 data	 shows	 that	 male	 puberty	 genes	 are	
enriched	in	CNS	tissues,	consistent	with	findings	in	AAM35	and	is	expected	given	important	role	of	
the	 hypothalamic-pituitary-gonadal	 axis	 which	 controls	 aspects	 of	 the	 reproductive	 lifecycle.	
Indeed,	hypothalamus	and	pituitary	tissues	were	among	the	most	enriched	for	expression.	This	
may	also	reflect	an	enrichment	 for	BMI-mediated	pathways,	as	BMI	 is	known	to	have	a	strong	
influence	 on	 puberty	 timing	 and	 has	 a	 CNS-enriched	 expression	 pattern	 related	 to	 appetite	
regulation155.		
In	addition	to	genes	and	pathways	with	known	reproductive	function,	the	novel	loci	also	revealed	
unexpected	 insights	 into	 factors	related	 to	puberty	 timing.	While	a	darkening	of	hair	and	skin	
pigmentation	 has	 consistently	 been	 reported	 in	 children	 on	 European	 ancestry153,154,	 this	 has	
never	been	systematically	assessed	using	genetic	methods.	The	 results	of	 the	MR	analyses	 for	
natural	hair	colour	to	puberty	timing	yielded	robust	evidence	for	widespread	shared	biological	
mechanisms	influencing	these	two	traits.	The	overall	effect	sizes	are	larger	in	men,	and	the	graded	
trend	for	earlier	puberty	with	darkening	hair	 is	not	apparent	 in	women.	This	 is	perhaps	to	be	
expected	 as	 it	 has	 been	 reported	 that	 androgens	 have	 a	 stronger	 stimulatory	 effect	 on	
melanogenesis	compared	to	oestrogens156.	A	plausible	biological	link	exists	in	the	pituitary	pro-
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peptide	 pro-opiomelanocortin	 (POMC),	 which	 contains	 several	 peptides	 which	 influence	












this	 male	 puberty	 meta-GWAS	 confirm	 many	 of	 these	 findings,	 including	 strong	 inverse	
associations	 with	 diabetes,	 cardiovascular	 conditions	 and	 adult	 BMI,	 compared	 to	 positive	
correlations	 with	 favourable	 health	 and	 social	 outcomes	 including	 perceived	 health	 and	
educational	attainment.		
MR	 analyses	 demonstrated	 a	 causal	 influence	 of	 earlier	 male	 puberty	 on	 decreased	 lifespan.	
Earlier	puberty	has	also	previously	been	shown	to	be	causally	related	to	prostate	cancer	when	
accounting	for	BMI35,	though	the	MR	analyses	conducted	here	did	not	find	evidence	to	support	
this.	 However	 the	 directions	 of	 effect	 were	 consistent	 with	 expectations	 based	 on	 previous	
findings;	 therefore	 it	 is	 premature	 to	dismiss	 the	possibility	 of	 a	 causal	 relationship	based	on	
borderline-insignificant	 P-values.	 If	 these	 results	 can	 be	 confirmed	 in	 larger	 studies,	 this	
represents	 an	 interesting	 and	 complex	 dynamic,	 whereby	 increased	 BMI	 has	 directionally	





This	 study	 presents	 a	 vast	 improvement	 in	 the	 sample	 size	 for	 discovery	 of	 genetic	
variants	associated	with	male	puberty	timing,	a	trait	which	has	previously	been	poorly	
characterised.	 The	 MTAG	 framework	 allows	 incorporation	 of	 data	 from	multiple	 and	
potentially	overlapping	cohorts	from	UK	Biobank	in	addition	to	the	23andMe	data	used	
previously.	 MTAG	 also	 allows	 for	 the	 inclusion	 of	 data	 on	 other	markers	 for	 puberty	
timing	(i.e.	facial	hair	onset)	to	the	previously	
 74 
validated	 age	 of	 voice	 breaking,	 and	 the	 four-fold	 increase	 in	 sample	 size	 resulting	 from	 this	
represents	a	significant	advance	in	statistical	power	for	discovery.	This	is	evidenced	by	the	large	




assumptions	 of	 ignoring	 sampling	 variation	 and	 the	 adequate	 capture	 of	 sample	 overlap	may	




a	 single	 stratum,	 and	 the	 maxFDR	 calculation	 provided	 strong	 justification	 that	 this	 key	
assumption	was	not	violated.				











the	 culmination	 of	 ‘early-life’	 and	 transition	 into	 adulthood.	 This	 chapter	 summarises	 the	

































This	 study	 was	 conceived	 in	 collaboration	 with	 colleagues	 at	 the	 MRC	 Epidemiology	 Unit,	
including	 Dr.	 Ken	 Ong,	 Dr.	 Felix	 Day	 and	 Dr.	 John	 Perry.	 In	 addition,	 Dr.	 Laura	 Wittemans	






































common	 comorbidities	 of	 obesity	 (including	 high	 blood	 pressure,	 cardiovascular	 disease	 and	
diabetes),	observational	studies	have	not	shown	a	consistent	relationship	between	lower	weight	
at	birth	and	higher	BMI	in	adulthood.	It	has	been	suggested	that	low	birth	weight	may	instead	lead	
to	 adaptations	 which	 influence	 the	 distribution	 of	 body	 fat	 towards	 a	 more	 central	 and	
metabolically	unhealthy	pattern.	While	there	is	some	evidence	for	this	from	observational	studies,	
it	has	not	been	systemically	investigated	using	genetic	methods.	In	this	chapter	I	describe	such	a	
study,	 using	 genetic	 variants	 associated	with	 birth	weight	 in	 combination	with	 results	 from	a	
































Exposures	 which	 influence	 health	 outcomes	 can	 begin	 very	 early	 in	 the	 life	 course.	 This	 is	
exemplified	by	observed	associations	between	birth	weight	and	risk	of	cardio-metabolic	disease	
in	 later-life.	 	 Associations	 between	 low	 birth	 weight	 and	 higher	 blood	 pressure,	 T2D	 and	
dyslipidaemia	 in	 adulthood	 have	 consistently	 been	 reported157–161.	 These	 effects	 of	 low	 birth	
weight	may	begin	 to	manifest	even	 in	early	childhood,	with	metabolic	abnormalities	 including	
insulin	resistance	and	abnormal	inflammatory	markers	having	been	reported	in	children	as	young	
as	two	years162,163.	At	the	opposite	end	of	the	spectrum,	high	birth	weight	has	also	been	shown	to	
be	a	risk	 factor	 for	poor	metabolic	health,	with	studies	demonstrating	 increased	prevalence	of	
T2D	and	CVD	among	individuals	born	at	high	weight	for	gestational	age	(HGA)164,165.	Such	findings	
highlight	the	importance	of	healthy	birth	weight	in	normal	growth	and	development,	and	identify	








the	 foetus	 in	 response	 to	 stressors	 such	 as	maternal	malnutrition	 can	 explain	 the	 heightened	
health	 risks	 that	 are	 regularly	 observed	 in	 low	 birth	 weight	 individuals166,167.	 This	 has	 been	
termed	 ‘foetal	 programming’,	 and	 is	 supported	 primarily	 by	 evidence	 indicating	 increased	
prevalence	of	obesity	and	other	indicators	of	poor	cardio-metabolic	health	in	offspring	born	to	













approximating	 an	 adverse	 intra-uterine	 environment,	 showed	 no	 such	 association	with	 blood	
pressure	in	offspring.	Based	on	this	the	authors	suggested	that	shared	genetic	factors,	rather	than	

















children	 and	 adults176–178.	 Positive	 associations	 have	 also	 been	 reported	 for	 total	 fat	 mass	





resolve	 the	 effects	 of	 central	 adiposity	 on	 metabolic	 health183–185.	 This	 is	 due	 to	 the	 greater	
metabolic	 activity	 of	 VAT	 as	 compared	 to	 SAT,	 making	 it	 a	 stronger	 predictor	 of	 metabolic	
dysfunction.	Studies	specifically	investigating	the	effects	of	VAT	and	SAT	have	suggested	that	birth	













mechanism	 linking	 population	 variation	 in	 birth	 weight	 with	 differential	 disease	 risk.	 While	
studies	using	BMI	as	the	measure	of	adiposity	have	produced	mixed	results,	there	is	evidence	for	





detail,	 by	 partitioning	 fat	 and	 lean	mass	 into	 specific	 body	 compartments.	 	 In	 this	 chapter,	 I	
describe	 a	 study	 which	 utilises	 DEXA	 scan	 data	 from	 several	 large-scale	 cohort	 studies	 to	
investigate	the	association	between	birth	weight	and	adult	body	composition.	To	begin,	I	perform	
meta-analysis	of	summary	statistics	from	three	individual	GWAS	of	fat	and	lean	mass	in	14	body	







































them	 more	 suitable	 for	 use	 in	 large-scale	 population-based	 studies.	 Furthermore,	 validation	
studies	comparing	fat	and	lean	mass	estimates	derived	from	DEXA	with	MRI	estimates	show	a	
high	 correlation	of	whole	body	 fat	 and	 lean	mass	measurements	between	 the	 two	 techniques	
(R=0.99	and	0.97,	respectively)189.	
	
Software	 developed	 by	 DEXA	 manufacturers	 delimits	 seven	 distinct	 body	 regions:	 android,	
gynoid,	 legs,	 arms,	 trunk,	 head	and	pelvis190.	 These	 regions	 are	depicted	 in	Figure	4.1.	 In	 the	
android	region,	subcutaneous	fat	thickness	is	also	estimated	and	used	to	calculate	a	variable	for	
visceral	 fat	 mass	 by	 subtracting	 subcutaneous	 android	 fat	 mass	 from	 total	 android	 fat	 mass	
(Figure	 4.1	 B).	 In	 total,	 body	 composition	 measurements	 were	 available	 for	 nine	 fat	 mass	
compartments	 (android,	 gynoid,	 trunk,	 leg,	 arm,	 peripheral,	 visceral,	 subcutaneous	 and	 total	






the	 manufacturer	 used	 to	 assess	 images	 (version	 14.10.022,	 GE	 Healthcare).	 Images	 were	
manually	 reviewed	 by	 trained	 technicians,	 with	 low	 quality	 images	 discarded.	 In	 Fenland,	
scanning	was	 performed	on	11,869	participants,	with	 11,741	passing	 quality	 control	while	 in	



















specific	 covariates.	 The	 residuals	 from	 linear	 regression	 models	 were	 rank-based	 inverse	
normally	 transformed.	 All	 transformations	 were	 performed	 separately	 in	 men	 and	 women.	
Additionally,	 to	 account	 for	 overall	 body	 size	 as	 a	 potential	 confounding	 factor	models	 were	
adjusted	 for	 total	 fat	 mass	 for	 fat	 compartments	 and	 for	 height	 squared	 in	 lean	 mass	
compartments.		
 83 
GWAS	on	 autosomal	 genetic	 variants	were	 conducted	 separately	 for	 each	of	 the	 studies,	with	












To	 combine	 estimates	 across	 the	 three	 studies,	 fixed-effect	 meta-analysis	 were	 performed	 in	
























As	 a	 sensitivity	 analysis,	 hierarchical	 clustering	was	 also	 performed	 on	 birth	weight	 variants	







and	 multivariate	 Mendelian	 randomisation	 analyses	 were	 conducted.	 The	 300	 birth	 weight	
autosomal	variants	were	used	to	construct	the	genetic	instruments	for	the	exposure,	modelling	
foetal	and	maternal	effects	separately.	Estimates	 for	 the	variants’	effects	on	birth	weight	were	
obtained	 from	 the	 foetal	and	maternal-specific	birth	weight	GWASs,	and	aligned	such	 that	 the	
birth	weight-increasing	 allele	was	 considered	 the	 effect	 allele.	 For	 the	 univariate	MRs,	 a	 two-
sample	 IVW	 approach	was	 used	 to	 regress	 variants’	 effect	 on	 birth	 weight	 against	 the	 effect	




!!! =	$"!"! +	$#!#! +	&$!,								&$!~((0, ,-(!!!)&)	 [1]	
	
Where	!!! 	 ,	!"! 	 and	!#! 	 are	 the	 estimates	 for	 the	 association	 between	 the	 jth	variant	 and	 the	
outcome	(i.e.	the	DEXA	variable),	foetal	birth	weight	and	maternal	birth	weight,	respectively.	$" 	
and	$#	 are	 the	 effects	 of	 the	 foetal	 and	maternal	 genetic	 variants	 on	 the	 outcome,	while	 &$! 	




























birth	 weight-increasing	 alleles	 at	 both	 variants	 at	 this	 locus	 were	 associated	 with	 decreased	
peripheral	fat	and	increased	trunk	fat.	In	addition	the	variant	rs75034466	was	associated	with	
decreased	leg	fat	and	increased	visceral	fat.	Another	variant,	rs1480470	locating	in/near	the	gene	
for	HMGA2,	also	showed	associations	with	 fat	mass	 in	multiple	compartments.	Here,	 the	birth	
weight-increasing	 allele	 was	 associated	 with	 decreased	 trunk	 and	 android	 fat	 and	 increased	
peripheral	 fat.	 Variants	 at	 this	 locus	 have	 also	 been	 associated	 with	 a	 number	 of	 relevant	
anthropometric	 and	metabolic	 traits	 including	 BMI-adjusted	 hip	 circumference194,	 T2D195	 and	







Variant	 Chr:Pos	 Nearest	Gene	 SEM	annotation	 Associated	trait	 β	(S.E.)*	 P-value	



























effect	 in	 foetal	 and	 maternal	 birth	 weight	 GWAS	 and	 were	 excluded	 from	 the	 analysis).	 The	
clustered	heat	map	is	shown	in	Figure	4.2,	with	all	effect	estimates	aligned	to	the	birth	weight-
increasing	allele.	As	expected,	the	primary	clustering	of	body	composition	variables	along	the	x-
axis	 separates	 central	 fat	 compartments	 (visceral,	 android	 and	 trunk	 fat	mass)	 from	all	 other	
variables	while	a	secondary	cluster	separates	peripheral	fat	mass	from	lean	mass	compartments.	
Along	the	y-axis	the	optimal	number	of	clusters	was	determined	by	the	silhouette	method,	which	
revealed	 two	distinct	 clusters.	The	 first	 cluster	 (Cluster	1)	was	 comprised	of	 124	SNPs	which	
generally	showed	negative	associations	with	central	fat	compartments	and	positive	associations	
with	 peripheral	 fat	 mass	 compartments.	 Within	 this	 cluster,	 a	 subset	 of	 variants	 showing	
additional	 positive	 associations	 with	 lean	 mass	 compartment	 was	 also	 observed.	 The	 larger	
second	cluster	(Cluster	2;	N=166	SNPs)	appears	to	be	more	heterogeneous,	with	one	subset	of	



















































pathway	 characterised	 by	 variants	 with	 decrease	 central	 fat	 mass	 deposition	 in	 favour	 of	
peripheral	 deposition)	 are	 insulin	 signalling	 (FDR=2.0×10-3),	 carbohydrate	 absorption	
(FDR=9.8×10-3)	and	oxytocin	signalling	(FDR=0.04).	Pathways	unique	to	Cluster	2,	characterised	
by	variants	associated	with	increased	central	fat	deposition	while	decreasing	peripheral	fat	mass	







on	 the	 subsets	 of	 variants	 identified	 by	 hierarchical	 clustering.	 The	 proportion	 of	 variants	
classified	as	‘foetal-only’	and	‘maternal-only’	by	the	SEM	models	were	not	significantly	different	
between	Clusters	1	and	2	(χ2	p-value=0.98).	To	further	investigate	foetal	and	maternal-specific	
effects	on	body	 composition,	hierarchical	 clustering	was	performed	using	 the	 subsets	of	 SNPs	
































assess	 the	 effect	 of	 birth	 weight	 on	 compartmental	 body	 composition,	 MR	 analyses	 were	








(depending	 on	 the	 model	 being	 considered)	 were	 adjusted	 for.	 Such	 analyses	 enable	 the	











arm	 fat	which	 became	 statistically	 significant	 (β=	 -0.23,	 P=3.0×10-3).	 For	 lean	mass	 variables,	







effects,	 the	 associations	 with	 all	 lean	 mass	 variables	 are	 completely	 attenuated	 (minimum	
P=0.21).	However,	 the	 associations	with	 the	majority	 of	 fat	mass	 variables	 remained	 strongly	
significant	 in	 the	multivariate	MR	models.	Higher	 genetically	 predicted	maternal	 birth	weight	
conferred	lower	fat	mass	in	central	compartments	including	the	android	(β=	-0.41,	P=1.0×10-7),	
trunk	(β=	-0.44,	P=9.5×10-8)	and	visceral	(β=	-0.37,	P=1.5×10-6)	regions,	independently	of	effects	
of	 the	 foetal	 genome.	 In	 contrast,	 higher	maternally-driven	 birth	weight	 was	 associated	with	
increased	fat	deposition	in	peripheral	compartments	including	the	arm	(β=	0.21,	P=3.2×10-3)	and	
leg	 (β=	 0.37,	 P=3.1×10-6)	 regions	 as	 well	 as	 increased	 overall	 peripheral	 fat	 mass	 (β=	 0.41,	
P=4.1×10-7).	The	lone	exception	to	this	trend	is	gynoid	fat	mass	which	did	not	remain	significantly	












									Univariatea										 							Multivariateb								 									Univariatea											 									Multivariateb										
Beta	(SE)	 P-value	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	
Central	Fat	Mass	Compartments	
Android	 -0.32	(0.04)	 2.0×10-20	 0.12	(0.08)	 0.13	 -0.22	(0.04)	 2.2×10-9	 -0.41	(0.08)	 1.0×10-7	
Trunk		 -0.35	(0.04)	 1.9×10-24	 0.12	(0.09)	 0.18	 -0.26	(0.04)	 1.1×10-11	 -0.44	(0.08)	 9.5×10-8	
Visceral		 -0.29	(0.04)	 2.3×10-16	 0.11	(0.08)	 0.17	 -0.20	(0.04)	 1.3×10-7	 -0.37	(0.07)	 1.5×10-6	
Peripheral	Fat	Mass	Compartments	
Arm		 0.04	(0.04)	 0.21	 -0.23	(0.08)	 3.0×10-3	 -0.05	(0.04)	 0.17	 0.21	(0.07)	 3.2×10-3	
Gynoid		 0.17	(0.04)	 5.7×10-7	 0.02	(0.08)	 0.78	 0.16	(0.04)	 3.4×10-5	 0.18	(0.07)	 0.04	
Leg		 0.33	(0.04)	 4.5×10-21	 -0.07	(0.09)	 0.43	 0.25	(0.04)	 2.2×10-11	 0.37	(0.08)	 3.1×10-6	
Peripheral.		 0.32	(0.04)	 1.2×10-20	 -0.12	(0.09)	 0.16	 0.23	(0.04)	 1.6×10-9	 0.41	(0.08)	 4.1×10-7	
Subcutan.	 -0.01	(0.04)	 0.88	 -0.02	(0.07)	 0.83	 -0.01	(0.04)	 0.77	 0.01	(0.07)	 0.93	
Lean	Mass	Compartments	
Android		 0.19	(0.04)	 2.1×10-8	 0.19	(0.07)	 0.01	 0.24	(0.04)	 3.0×10-10	 0.06	(0.07)	 0.37	
App.		 0.16	(0.04)	 2.8×10-6	 0.12	(0.07)	 0.10	 0.18	(0.04)	 8.4×10-7	 0.07	(0.07)	 0.28	
Arm		 0.12	(0.04)	 2.0×10-20	 0.11	(0.07)	 0.11	 0.15	(0.04)	 7.4×10-5	 0.04	(0.07)	 0.54	
Gynoid		 0.13	(0.04)	 1.5×10-4	 0.14	(0.07)	 0.04	 0.17	(0.04)	 8.8×10-6	 0.03	(0.07)	 0.68	
Leg		 0.16	(0.04)	 2.6×10-6	 0.11	(0.07)	 0.12	 0.18	(0.04)	 1.2×10-6	 0.08	(0,07)	 0.23	
Total		 0.20	(0.04)	 5.2×10-9	 0.16	(0.07)	 0.03	 0.23	(0.04)	 5.0×10-10	 0.09	(0.07)	 0.21	












shown	 that	 shared	 genetic	 factors	may	 underlie	 these	 associations.	 Results	 from	 non-genetic	















that	 the	 clustering	 of	 SNPs	 that	 arise	 are	 also	 likely	 to	 be	 biologically	 meaningful.	 Primary	
clustering	of	genetic	variants	appeared	to	be	driven	by	two	subsets	with	opposite	directions	of	
effect	on	central	fat	mass	compartments	(android,	trunk	and	visceral)	and	peripheral	fat	mass	in	
the	 gynoid	 and	 leg	 regions.	 Pathway	 analysis	 in	 STRING	 found	 non-overlapping	 pathways	




a	 key	 determinant	 of	 foetal	 growth	 via	 stimulation	 of	 foetal	 insulin	 production,	 with	 lower	
maternal	glucose	levels	associated	with	lower	birth	weight	in	offspring199.	Thus,	shared	genetic	












foetal	 programming,	 as	 maternally-predicted	 birth	 weight	 adjusted	 for	 foetal	 effects	 can	 be	
thought	of	 as	 representing	 the	 influence	of	 the	 intra-uterine	 environment.	This	 is	 in	 line	with	
evidence	from	twin	studies,	which	have	shown	that	among	monozygotic	twin	pairs,	the	heavier	
twin	at	birth	tended	to	have	a	more	favourable	body	composition	as	adults200.	Thus,	this	line	of	














of	 body	 composition,	 which	 allows	 for	 examination	 of	 specific	 patterns	 on	 fat	 and	 lean	mass	
distribution	which	are	unattainable	though	other	methods	used	previously.	In	addition,	the	use	of	















This	 chapter	 presents	 evidence	 for	 a	 causal	 association	 between	 low	 birth	weight	 and	 a	 less	
metabolically	healthy	distribution	of	fat	mass	in	adulthood.	This	appears	to	be	driven	largely	by	
maternal	 factors	 which	 may	 influence	 birth	 weight	 via	 the	 intra-uterine	 environment.	 This	
provides	support	for	the	involvement	of	foetal	programming	in	mediating	the	association	between	

















































































































re-analysis	 of	 the	 genetic	 risk	 score	 for	 methylation	 was	 conducted	 by	 Dr.	 Felix	 Day	 (MRC	
Epidemiology	Unit,	University	 of	 Cambridge)	 and	 is	 included	here	 for	 completeness.	All	 other	






























The	 regulation	 of	 gene	 expression	 is	 a	 central	 theme	 of	 biology,	 and	 plays	 a	 critical	 role	 in	













previously	 reported	 results	which	have	 suggested	 an	overarching	directional	 effect	 of	BMI	on	

























Epigenetics	 describes	 a	 group	 of	 modifications	 to	 DNA	 that	 do	 not	 involve	 editing	 of	 the	






RNA-mediated	 silencing	 of	 genes.	 Among	 these,	 DNA	methylation	 is	 perhaps	 the	most	widely	
































DNA	 methylation	 is	 highly	 conserved	 throughout	 mitosis	 in	 humans,	 and	 is	 also	 maintained	







of	 cancer214,	 systemic	 lupus	 erythromatosus215	 and	 fragile	 X	 syndrome216.	 In	 recent	 years,	 the	














years	 through	 the	development	of	 epigenome-wide	association	 studies	 (EWAS).	These	 studies	
have	performed	hypothesis-free	tests	at	hundreds	of	thousands	of	differentially	methylated	loci,	
yielding	 new	 insights	 into	 the	 role	 of	 DNA	 methylation	 in	 determining	 BMI	 and	 body	
composition218,219.	Dick	et	al.	described	the	first	such	study,	which	identified	three	differentially	
methylated	 regions	 (DMRs)	 in	 the	 hypoxia-inducible	 factor	 3	 alpha	 (HIF3A)	 gene	 that	 were	










mediated	 by	 DNA	 methylation223.	 Genetic	 studies	 of	 AAM	 have	 demonstrated	 that	 genes	
associated	with	puberty	timing	are	enriched	in	known	imprinted	regions	of	the	genome,	including	
rare	variants	 in	the	MKRN3	and	DLK1	 loci	which	show	associations	with	puberty	timing	when	
inherited	 from	 the	 father	 but	 not	 when	 inherited	 from	 the	 mother35.	 While	 further	 work	 is	














al.	 assessed	 the	 directionality	 of	 the	 association	 between	 methylation	 and	 BMI	 at	 the	
aforementioned	 HIF3A	 gene	 using	 long-term	 longitudinal	 follow-up,	 determining	 that	
methylation	at	this	locus	was	likely	the	consequence	rather	than	the	cause	of	increased	BMI224.	
Others	 have	 attempted	 to	 employ	 instrumental	 variable	 analysis	 to	 address	 the	 question	 of	
causality.	Mendelson	et	al.	used	such	an	approach	to	identify	one	locus	in	the	SREBF1	gene	which	



















and	 health	 traits	 of	 interest	 remains	 open.	 Understanding	 the	 nature	 of	 these	 associations	 is	
essential	if	the	findings	from	epigenetic	studies	are	to	be	translated	to	potential	clinical	or	public	
health	 benefits.	 	 The	 interest	 in	 the	 field	 of	 epigenetics	 has	 led	 to	 the	 generation	 of	 publicly	
available	resources	linking	genetic	variation	to	methylation	levels.	In	this	chapter	I	make	use	of	
several	of	these	resources,	as	well	as	applying	a	novel	method	for	the	detection	of	genetic	variants	





















































































































association	 statistics	 from	 GWAS	 to	 identify	 associations	 between	 expression	 of	 genes	 and	











Infinium	 Human	 Methylation	 450k	 beadchips.	 Initial	 quality	 control	 was	 performed	 per	
manufacturer	 specifications,	 with	 methylation	 intensity	 values	 corrected	 using	 the	 Illumina	
Background	 Correction	 algorithm	 implemented	 using	 the	 R	 package	 ‘minfi’.	 Methylation	
























any	 methylation-trait	 associations	 identified	 by	 EWAS-FUSION	 may	 be	 interpreted	 as	 being	
causal.	We	applied	summary	statistics	 from	both	the	GIANT-UK	Biobank	BMI	meta-analysis	as	
well	as	the	voice	breaking	meta-analysis	(described	in	Chapter	3)	to	EWAS-FUSION,	in	order	to	




















effect	 of	 methylation	 on	 BMI	 (Table	 5.1).	 Three	 of	 these	 were	 statistically	 significant	 after	
application	of	a	Bonferroni-corrected	P-value	threshold:	rs115616784	(meQTL	for	cg26663590	
in/near	NFATC2IP,	P=2.7×10-7);	rs6778735	(meQTL	for	cg00108715	in/near	NT5DC2,	P=	1.1×10-
6);	 and	 rs2747429	 (meQTL	 for	 cg00094412	 in/near	GABBR1,	 P=8.5×10-6).	 Methylation	 at	 the	
NFATC2IP	locus	has	previously	been	implicated	as	having	a	causal	effect	on	BMI221,	while	NT5DC2	
and	GABBR1	 represent	novel	 findings.	Both	NFAT2CIP	 and	NT5DC2	 show	positive	associations	
with	BMI,	(i.e.	increased	methylation	at	these	loci	confer	higher	BMI).	Conversely	the	association	
for	GABBR1,	which	encodes	the	receptor	for	gamma-aminobutyric	acid	(GABA,	the	main	inhibitory	
neurotransmitter)	was	 in	 the	 opposite	 direction	 (increased	methylation	 leading	 to	 decreased	
BMI).	In	summary,	this	repeated	analysis	of	existing	data	using	an	independent	sample	to	identify	
meQTLs	as	instrumental	variables	confirmed	the	one	casual	association	of	methylation	on	BMI	
















	 	 	 	 	 				IVW	MR	estimate					
MVP	 Chr:	pos	 Nearest	gene	 Sentinel	meQTL	 EA/OA	 Z-score	 P-value	
cg26663590	 16:	28,959,310	 NFATC2IP	 rs115616784	 A/G	 5.18	 2.2×	10-7ϯ	
cg00108715	 3:	52,565,015	 NT5DC2	 rs6778735	 T/C	 4.87	 1.1×	10-6ϯ	
cg00094412	 6:	29,592,854	 GABBR1	 rs2747429	 C/T	 -4.45	 8.5×	10-6ϯ	
cg06559575	 12:	53,490,352	 IGFBP6	 rs10876407	 A/T	 -3.47	 5.2×	10-4	
cg07682160	 19:	18,959,935	 UPF1	 rs7250622	 G/A	 -3.05	 2.3×	10-3	
cg05063895	 16:	2,073,518	 SLC9A3R2	 rs28698483	 C/T	 3.00	 2.7×	10-3	
cg27614723	 15:	92,399,897	 SLCO3A1	 rs7165398	 C/T	 2.83	 4.6×	10-3	
cg03523676	 14:	24,540,235	 CPNE6	 rs7146599	 G/A	 2.73	 6.3×	10-3	
cg16578636	 10:	92,987,457	 PCGF5	 rs2648718	 T/C	 2.57	 0.01	
cg10717869	 1:	205,780,912	 SLC41A1	 rs4396169	 T/C	 2.50	 0.01	
cg08726900	 16:	89,550,474	 ANKRD11	 rs2019604	 G/T	 2.45	 0.01	
cg00431050	 10:	103,985,730	 ELOVL3	 rs61873698	 T/G	 -2.44	 0.01	
cg23232188	 3:	121,556,543	 EAF2	 rs9854539	 G/A	 2.26	 0.02	
cg12593793	 1:	156,074,135	 LMNA	 rs915179	 G/A	 2.26	 0.02	
cg08443038	 16:	89,006,877	 CBFA2T3	 rs491224	 A/G	 2.14	 0.03	
cg00863378	 16:	56,549,757	 BBS2	 rs72814488	 C/T	 -2.12	 0.03	
cg24679890	 19:	17,246,356	 MYO9B	 rs111366154	 T/C	 2.10	 0.04	
cg16163382	 2:	37,938,640	 CDC42EP3	 rs9808547	 C/G	 -2.07	 0.04	
cg26403843	 5:	158,634,085	 RNF145	 rs6556405	 C/T	 2.06	 0.04	
cg06192883	 15:	52,554,171	 MYO5C	 rs71472932	 A/G	 -2.05	 0.04	
cg10438589	 4:	14,531,493	 LINC00504	 rs16890352	 G/A	 2.05	 0.04	
cg09777883	 11:	112,093,696	 BCO2	 rs67245191	 A/G	 2.03	 0.04	
cg02650017	 17:	47,301,614	 PHOSPHO1	 rs850523	 C/T	 -1.97	 0.05	
cg16846518	 3:	128,062,608	 EEFSEC	 rs2687729	 G/A	 1.93	 0.05	





























































MVP	 Chr:	pos	 Nearest	Gene	 Beta	(S.E.)	 P-value	 SNP		 Gene	 Dist.	(b.p.)	
cg13314394	 2:	628,958	 TMEM18	 -19.0	(1.0)	 7.6×10-79	 -	 rs13021737	 TMEM18	 3,390	
cg09781307	 11:	27,648,324	 BDNF-AS	 -13.0	(1.0)	 2.4×10-41	 -	 rs11030104	 BDNF	 36,193	
cg06941159	 16:	28,875,210	 SH2B1	 12.0	(1.0)	 9.1×10-35	 Yes	 rs2650492	 SBK1	 541,799	
cg17351154	 19:	46,181,428	 GIPR	 12.1	(1.0)	 7.0×10-34	 Yes	 rs2287019	 QPCTL	 20,744	
cg12177314	 1:	177,841,709	 SEC16B	 11.4	(1.0)	 6.0×10-30	 -	 rs543874	 SEC16B	 47,771	
cg00337662	 15:	68,113,328	 SKOR1	 -11.0	(1.0)	 4.1×10-29	 -	 rs16951275	 MAP2K5	 36,160	
cg08875605	 3:	185,798,025	 ETV5	 11.2	(1.0)	 7.0×10-29	 -	 rs1516725	 ETV5	 25,979	
cg15604733	 6:	51,295,164	 PKHD1	 -11.0	(1.0)	 3.8×10-28	 -	 rs2207139	 TFAP2B	 449,674	
cg06117072	 6:	50,791,385	 TFAP2B	 -11.0	(1.0)	 3.4×10-27	 -	 rs2207139	 TFAP2B	 54,105	
cg00760992	 12:	50,223,054	 LOC100286844	 9.9	(1.0)	 5.3×10-23	 -	 rs7138803	 BCDIN3D	 24,414	
cg18129748	 3:	49,941,408	 MST1R	 -9.4	(1.0)	 7.4×10-21	 -	 >	1	MB	 -	 -	
cg10061532	 1:	201,886,748	 LMOD1	 9.1	(1.0)	 5.8×10-20	 Yes	 rs2820292	 NAV1	 102,461	
cg09256413	 1:	72,566,690	 NEGR1	 -8.4	(1.0)	 3.2×10-17	 -	 rs3101336	 NEGR1	 184,495	
cg24210813	 17:	46,669,644	 HOXB-AS3	 8.2	(1.0)	 3.0×10-16	 Yes	 >	1	MB	 -	 -	
cg27466709	 17:	1,844,037	 RTN4RL1	 7.9	(1.0)	 2.4×10-15	 Yes	 rs9914578	 SMG6	 161,099	
cg22814740	 1:	78,442,554	 FUBP1	 7.7	(1.0)	 1.5×10-14	 -	 rs12401738	 FUBP1	 223,205	
cg14672496	 18:	21,087,552	 C18orf8	 -7.4	(1.0)	 1.5×10-13	 -	 rs1808579	 C18orf8	 17,336	
cg15770687	 7:	76,625,569	 DTX2P1-UPK3BP1-
PMS2P11	
7.3	(1.0)	 2.8×10-13	 -	 rs2245368	 PMS2L11	 17,426	
cg00927699	 21:	46,493,289	 SSR4P1	 7.2	(1.0)	 6.6×10-13	 -	 >	1	MB	 -	 -	
cg06632762	 1:	110,230,545	 GSTM1	 -7.2	(1.0)	 6.7×10-13	 Yes	 rs17024393	 GNAT2	 75,857	
cg16926213	 1:	1,841,314	 CALML6	 7.1	(1.0)	 1.7×10-12	 Yes	 >	1	MB	 -	 -	
cg10026317	 1:	47,694,919	 TAL1	 6.8	(1.0)	 1.4×10-11	 -	 rs977747	 TAL1	 10,242	
cg16046214	 5:	170,289,848	 RANBP17	 -6.7	(1.0)	 2.6×10-11	 Yes	 >	1	MB	 -	 -	








MVP	 Chr:	pos	 Nearest	Gene	 Beta	(S.E.)	 P-value	 SNP		 Gene	 Dist.	(b.p.)	
cg02370877	 8:	76,316,876	 HNF4G	 6.6	(1.0)	 5.0×10-11	 -	 rs17405819	 HNF4G	 489,708	
cg00865973	 4:	102,709,336	 BANK1	 -6.6	(1.0)	 5.2×10-11	 -	 rs13107325	 SLC39AB	 479,373	
cg13634994	 9:	129,452,574	 LMX1B	 -6.6	(1.0)	 5.5×10-11	 -	 rs10733682	 LMX1B	 8,340	
cg15979035	 14:	93,698,870	 UBR7	 -6.5	(1.0)	 7.3×10-11	 -	 >	1	MB	 -	 -	
cg09002922	 5:	87,956,389	 LINC00461	 -6.7	(1.1)	 2.2×10-10	 -	 >	1	MB	 -	 -	
cg08321942	 19:	34,310,625	 KCTD15	 -6.3	(1.0)	 2.9×10-10	 -	 rs29941	 KCTD15	 1,093	
cg11784887	 8:	8,729,819	 MFHAS1	 -6.3	(1.0)	 3.0×10-10	 -	 >	1	MB	 -	 -	
cg22399598	 7:	74,570,700	 NCF1C	 -6.6	(1.1)	 6.7×10-10	 Yes	 rs1167827	 HIP1	 592,469	
cg11822372	 1:	151,115,635	 SEMA6C	 -6.2	(1.0)	 7.6×10-10	 -	 >	1	MB	 -	 -	
cg07177395	 14:	79,968,686	 NRXN3	 -6.1	(1.0)	 8.9×10-10	 -	 rs7141420	 NRXN3	 69,232	
cg04231319	 10:	21,824,447	 MLLT10	 -6.1	(1.0)	 1.0×10-9	 -	 >1	MB	 -	 -	
cg14263021	 9:	16,039,921	 CCDC171	 6.1	(1.0)	 1.4×10-9	 -	 rs4740619	 C9orf93	 405,595	
cg14418213	 9:	33,814,450	 UBE2R2	 6.0	(1.0)	 2.3×10-9	 Yes	 >	1	MB	 -	 -	
cg23702848	 14:	104,172,109	 XRCC3	 6.0	(1.0)	 2.6×10-9	 -	 >	1	MB	 -	 -	
cg03641066	 10:	77,542,423	 C10orf11	 5.9	(1.0)	 3.4×10-9	 -	 >	1	MB	 -	 -	
cg02407048	 7:	77,046,134	 PION	 5.9	(1.0)	 4.5×10-9	 -	 >	1	MB	 -	 -	
cg26115667	 14:	103,294,656	 TRAF3	 5.8	(1.0)	 8.5×10-9	 -	 >	1	MB	 -	 -	
cg09716613	 13:	33,000,534	 N4BP2L1	 -5.7	(1.0)	 1.2×10-8	 -	 >	1	MB	 -	 -	
cg26487582	 4:	25,322,200	 ZCCHC4	 -5.7	(1.0)	 1.5×10-8	 -	 >	1	MB	 -	 -	
cg04839131	 7:	150,644,715	 KCNH2	 -5.6	(1.0)	 1.7×10-8	 -	 >	1	MB	 -	 -	
cg16409650	 13:	96,744,161	 HS6ST3	 -5.6	(1.0)	 1.7×10-8	 -	 >	1	MB	 -	 -	
cg22722731	 4:	140,781,201	 MAML3	 5.6	(1.0)	 2.3×10-8	 -	 >	1	MB	 -	 -	
cg22274539	 12:	103,696,209	 C12orf42	 5.6	(1.0)	 2.3×10-8	 -	 >	1	MB	 -	 -	








MVP	 Chr:	pos	 Nearest	Gene	 Beta	(S.E.)	 P-value	 SNP		 Gene	 Dist.	(b.p.)	
cg25574965	 4:	52,728,090	 DCUN1D4	 -5.5	(1.0)	 3.9×10-8	 -	 >	1	MB	 -	 -	
cg19365176	 12:	116,963,394	 LINC00173	 -5.5	(1.0)	 4.2×10-8	 -	 >	1	MB	 -	 -	
cg03309328	 12:	99,525,864	 ANKS1B	 5.5	(1.0)	 4.7×10-8	 -	 >	1	MB	 -	 -	
cg08529931	 10:	88,124,564	 GRID1	 -5.5	(1.0)	 4.8×10-8	 -	 rs7899106	 GRID1	 713,660	
cg18884555	 22:	38,610,234	 MAFF	 -5.5	(1.0)	 5.0×10-8	 Yes	 NA	 NA	 NA	
cg11469321	 4:	104,021,294	 BDH2	 5.4	(1.0)	 7.0×10-8	 -	 rs13107325	 SLC39A8	 832,585	
cg24860938	 13:	27,998,603	 GTF3A	 5.4	(1.0)	 8.3×10-8	 -	 >	1	MB	 -	 -	
cg15400367	 13:	112,171,862	 TEX29	 -5.4	(1.0)	 8.5×10-8	 -	 >	1	MB	 -	 -	
cg14191369	 9:	130,996,177	 DNM1	 5.3	(1.0)	 1.0×10-7	 -	 >	1	MB	 -	 -	
cg05198960	 12:	133,309,102	 ANKLE2	 -5.2	(1.0)	 1.8×10-7	 -	 >	1	MB	 -	 -	
cg00647317	 7:	50,633,725	 DDC	 -5.2	(1.0)	 2.1×10-7	 -	 >	1	MB	 -	 -	
cg14750066	 12:	41,582,063	 PDZRN4	 5.2	(1.0)	 2.1×10-7	 Yes	 >	1	MB	 -	 -	
cg10869879	 12:	56,474,569	 ERBB3	 5.2	(1.0)	 2.4×10-7	 -	 >	1	MB	 -	 -	
cg02138778	 20:	25,172,755	 ENTPD6	 5.1	(1.0)	 2.6×10-7	 -	 >	1	MB	 -	 -	
cg16888547	 7:	3,2339,497	 PDE1C	 -5.1	(1.0)	 2.9×10-7	 -	 >	1	MB	 -	 -	
cg22466678	 12:	89,749,033	 DUSP6	 5.1	(1.0)	 3.4×10-7	 -	 >	1	MB	 -	 -	
cg19619956	 5:	176,967,557	 FAM193B	 -5.0	(1.0)	 4.7×10-7	 Yes	 >	1	MB	 -	 -	
cg19076659	 5:	137,688,057	 KDM3B	 5.0	(1.0)	 5.1×10-7	 -	 >	1	MB	 -	 -	
cg06670463	 4:	103,749,966	 UBE2D3	 5.0	(1.0)	 6.0×10-7	 -	 rs13107325	 SLC39A8	 561,257	












































This	 analysis	 was	 therefore	 repeated	 using	 the	 same	 data,	 with	 all	 GRS-predicted	 effects	 on	
methylation	expressed	as	positive	values,	which	removes	the	artificial	gap	at	the	centre.	Whereas	
the	originally	reported	correlation	was	strongly	positive	(R2=0.65),	the	effect	of	aligning	the	GRS-









































































































The	 two	 previously	 reported	 AAM	 loci	 which	 showed	 parent-of-origin	 effects,	 at	 DLK1	 and	




based	 on	 annotation	 of	 nearest	 gene.	 However	 two	 MVPs,	 cg03473532	 in/near	MKLN1	 and	
cg27513965	 in/near	 TFAP4,	 were	 both	 within	 1MB	 of	 known	 imprinted	 SNPs	 at	MEST	 and	





	 	 	 FUSION	(Voice	breaking)	 							FUSION	(BMI)								
MVP	 Chr:	pos	 Nearest	Gene	 Beta	(S.E.)	 P-value	 Z-score	 P-value	
cg01176694	 16:	14,289,232	 -	 14.2	(1.0)	 1.4×10-45	 -0.69	 0.49	
cg03473532	 7:	130,659,283	 MKLN1	 -10.4	(1.0)	 1.7×10-25	 -1.02	 0.31	
cg16786949	 3:	182,994,098	 -	 10.4	(1.0)	 4.7×10-25	 -0.33	 0.74	
cg02851062	 11:	122,354,193	 BSX	 -10.8	(1.0)	 6.0×10-25	 1.72	 0.09	
cg16228356	 17:	41,204,727	 -	 -10.1	(1.0)	 1.2×10-23	 -1.93	 0.05	
cg27631724	 1:	10,962,954	 C1orf127	 9.8	(1.0)	 1.5×10-22	 0.67	 0.50	
cg04744409	 6:	105,494,884	 -	 -24.5	(2.6)	 4.1×10-21	 2.79	 5.2×10-3	
cg25161029	 11:	122,351,182	 -	 -8.3	(1.0)	 2.3×10-15	 -1.12	 0.26	
cg07114886	 3:	51,720,986	 GRM2	 -7.7	(1.0)	 2.3×10-14	 4.13	 3.6×10-5	
cg25657713	 6:	100,145,429	 -	 7.8	(1.0)	 1.3×10-13	 -1.37	 0.17	
cg19984742	 20:	54,257,897	 MC3R	 7.2	(1.0)	 7.5×10-13	 -0.76	 0.45	
cg27554954	 15:	58,478,887	 ANXA2	 6.9	(1.0)	 6.5×10-12	 0.02	 0.98	
cg14184400	 3:	49,435,061	 AMT	 -6.9	(1.0)	 8.5×10-12	 0.90	 0.37	
cg17623882	 6:	41,881,589	 USP49	 6.7	(1.0)	 2.1×10-11	 2.65	 8.0×10-3	
cg19226099	 20:	54,257,492	 MC3R	 6.6	(1.0)	 4.2×10-11	 0.64	 0.52	
cg04106006	 11:	27,699,030	 BDNF	 -6.4	(1.0)	 1.2×10-10	 N/A	 N/A	
cg11882563	 14:	35,668,029	 -	 -6.4	(1.0)	 2.1×10-10	 -2.38	 0.02	
cg22156842	 3:	138,019,859	 TMEM22	 6.2	(1.0)	 4.7×10-10	 -4.82	 1.4×10-6	
cg08976101	 11:	44,284,999	 ALX4	 6.2	(1.0)	 6.1×10-10	 -0.86	 0.39	
cg11618529	 19:	63,643,920	 ZNF132	 -5.9	(1.0)	 2.9×10-9	 -0.90	 0.37	
cg12537728	 11:	13,266,172	 ARNTL	 5.9	(1.0)	 3.3×10-9	 -7.33	 2.4×10-13	
cg22456251	 15:	86,956,077	 MIR7-2	 5.9	(1.0)	 3.7×10-9	 -0.17	 0.87	
cg14515364	 2:	626,606	 -	 -5.8	(1.0)	 7.3×10-9	 16.20	 2.6×10-59	
cg00741624	 14:	92,967,142	 KIAA1409	 5.7	(1.0)	 1.2×10-8	 -5.46	 4.7×10-8	
cg27513965	 16:	4,261,434	 TFAP4	 -5.6	(1.0)	 2.2×10-8	 0.52	 0.61	
cg15129506	 2:	27,812,216	 -	 5.6	(1.0)	 2.5×10-8	 -4.14	 3.5×10-5	
cg11777420	 2:	120,486,403	 EPB41L5	 -5.4	(1.0)	 6.8×10-8	 N/A	 N/A	
cg09953425	 20:	32,914,810	 GGT7	 -5.3	(1.0)	 9.8×10-8	 2.52	 0.01	
cg03036210	 16:	88,431,592	 SPIRE2	 5.8	(1.1)	 1.5×10-7	 1.05	 0.29	
cg10527021	 4:	104,863,920	 -	 -5.2	(1.0)	 2.5×10-7	 0.64	 0.52	
cg03726525	 16:	68,764,798	 CLEC18C	 5.1	(1.0)	 2.8×10-7	 -6.98	 2.9×10-12	
cg18074954	 18:	43,041,490	 -	 -5.1	(1.0)	 3.0×10-7	 1.29	 0.20	
cg25281562	 12:	119,938,655	 C12orf43	 -5.1	(1.0)	 3.5×10-7	 -1.81	 0.07	
cg12277524	 1:	66,051,507	 PDE4B	 5.5	(1.1)	 3.6×10-7	 N/A	 N/A	
cg03461559	 17:	7,259,644	 NLGN2	 -5.1	(1.0)	 4.0×10-7	 -1.83	 0.07	
cg14378231	 1:	98,176,620	 -	 5.1	(1.0)	 4.0×10-7	 2.34	 0.02	
cg10483660	 13:	111,039,078	 -	 5.1	(1.0)	 4.3×10-7	 -4.46	 8.2×10-6	

























al.	 performed	 bi-directional	 MR	 analyses	 on	 187	 MVPs	 identified	 in	 an	 EWAS	 for	 BMI	 and	
concluded	 that	 BMI	 influenced	 methylation	 while	 the	 reverse	 pathway	 was	 less	 likely.	 This	










association	with	NFAT2CIP	 was	 confirmed,	 in	 addition	 to	 identifying	 two	 further	 loci	 in/near	
NT5DC2	 and	 GABBR1	 which	 also	 show	 evidence	 for	 a	 causal	 effect	 of	 methylation	 on	 BMI.	
Unfortunately,	performing	the	reverse	MRs	was	not	possible	as	the	summary	data	for	methylation	
was	not	available;	therefore	we	are	unable	to	provide	a	comparative	estimate	for	the	number	of	
























genes	and	 the	 initiation	of	puberty	 timing234.	However,	 these	 studies	have	 relied	on	assessing	
methylation	 in	 specific	 candidate	 genes,	 and	 large-scale	 genome-wide	 assessment	 studies	








































false	 positives	 because	 of	 sequence	 similarity239.	 It	may	 be	 that	 some	 or	 all	 of	 the	 non-GWAS	
associations	are	acting	as	trans-meQTLs.	Finally,	since	this	analysis	was	conducted	an	updated	









The	 influence	 of	 epigenetic	modifications	 on	 complex	 traits	 is	 an	 active	 area	 of	 research	 and	
debate.	In	the	case	of	BMI,	the	potential	of	DNA	methylation	to	causally	impact	this	trait	has	largely	
been	discounted	in	the	literature,	with	explanations	favouring	causality	in	the	opposite	direction.	
The	 results	 presented	 in	 this	 chapter	 therefore	 represent	 an	 important	 contribution	 to	 this	
debate,	with	the	identification	of	multiple	genomic	loci	where	variation	in	methylation	causally	


















































































































































have	 been	 shown	 to	 influence	 multiple	 reproductive	 conditions,	 indicating	 a	 large	 degree	 of	





for	 smaller	 studies	 and	 a	 limited	 numbers	 of	 traits	 to	 large-scale	 studies,	 with	 potentially	
thousands	of	phenotypes,	has	proven	challenging.	In	this	chapter	I	describe	a	study	which	aims	to	
mitigate	 some	 of	 the	 common	 pitfalls	 of	 PheWAS,	 by	 conducting	 genetic	 discovery	 for	 traits	
related	 to	reproduction	which	are	available	 in	 the	UK	Biobank	study.	 I	 conduct	GWAS	 for	181	
reproductive	traits,	the	majority	of	which	have	never	been	studied	using	genome-wide	genetic	























Aspects	 of	 reproductive	 health	 and	 fertility	 vary	 considerably	 in	 the	 population	 and	 have	
important	 implications	 for	 clinical	 outcomes	 and	 individual	wellbeing.	 Thus	 far	 in	 this	 thesis,	
















Breast	 Cancer	 Association	 Consortium	 (BCAC),	 PRACTICAL	 and	 ReproGen	 have	 identified	
hundreds	 of	 variants	 associated	with	 breast	 cancer243,	 prostate	 cancer143,244	 and	 the	 timing	 of	
reproductive	events35,245,	respectively.	Large-scale	genetic	discovery	has	also	been	conducted	for	
select	 other	 reproductive	 traits,	 identifying	 variants	 associated	 with	 PCOS41,	
endometriosis40,246,247,	 and	 benign	 prostate	 hyperplasia	 (BPH)248,249	 among	 other	 common	
conditions.	Such	studies	have	revealed	complex	polygenic	architecture	underlying	these	traits,	as	
well	 as	 providing	 evidence	 for	 a	 substantial	 amount	 of	 overlap	 of	 the	 genetic	 determinants	
influencing	different	reproductive	outcomes.	Moreover,	casual	inferences	have	made	use	of	the	
identified	variants,	 demonstrating	 that	 reproductive	 traits	 can	 influence	numerous	health	 and	
social	outcomes250–253.	
	
Despite	 this	 progress,	 genetic	 discovery	 for	many	 other	 less	 common	 reproductive	 traits	 and	
diseases	has	not	been	conducted.	Identification	of	genetic	determinants	from	a	broader	range	of	







As	 the	 field	 of	 statistical	 genetics	 progresses	 and	 GWAS	 summary	 statistics	 from	 ever	 larger	
studies	and	more	traits	become	available,	this	presents	the	opportunity	to	leverage	this	data	to	
gain	a	better	understanding	of	complex	trait	genetics.	In	recent	years,	phenome-wide	associations	










resource	 for	 identifying	 genetic	 variants	 with	 pleiotropic	 effects260.	 This	 is	 perhaps	 best	
exemplified	by	the	UK	Biobank	study,	which	provides	publicly	available	genotypic	data	on	it’s	over	
500,000	participants,	along	with	extensive	phenotypic	data	on	health,	socioeconomic	and	lifestyle	





for	by	applying	a	highly	restrictive	correction	 for	 the	multiple	 tests	being	run.	Secondly,	 these	
rapid	and	automated	approaches	often	maximise	efficiency	at	the	expense	of	fully	cleaned	and	





therefore	be	advantageous.	Limiting	the	number	of	 traits,	 for	example	to	only	 those	related	to	










however	 many	 of	 the	 approaches	 employed	 to	 date	 have	 not	 been	 able	 to	 fully	 exploit	 this	
potential.	In	this	chapter	I	describe	a	study	which	attempts	to	address	some	of	the	key	limitations	
of	 PheWAS	 methods	 which	 have	 previously	 been	 employed,	 in	 order	 to	 enhance	 our	





2) Applying	a	PheWAS	 framework	 to	 the	GWAS	results	 to	allow	 inferences	 to	be	made	at	
multiple	levels	of	genomic	resolution;	and	
3) To	create	a	genetic	atlas	of	reproductive	health,	to	be	called	“REPROWAS”,	for	use	in	future	








































participants	 living	 within	 35km	 of	 the	 UK	 Biobank	 Co-ordinating	 Centre	 in	 Stockport,	 UK	










UK	 Biobank	 electronic	 health	 record	 linkage	 provided	 further	 data	 on	 reproductive	 health	
outcomes	 in	 the	 form	 of	 International	 Classification	 of	 Disease,	 Version	 10	 (ICD-10)	 coded	














amend	 touchscreen	 responses.	 Conditions	 were	 coded	 by	 UK	 Biobank	 researchers	 using	 a	
hierarchical	classification	system,	divided	into	cancer	and	non-cancer	illnesses	(data	fields	20001	
and	 20002,	 respectively).	 Similar	 to	 ICD-10	 coding,	 the	 system	 uses	 four	 levels	 of	 increasing	


















on	 reported	 numbers	 of	 live	 births,	 spontaneous	 miscarriages,	 stillbirths	 and	 terminations.	
Women	who	had	never	been	pregnant	were	then	excluded	from	analyses	for	pregnancy-related	
outcomes.	For	age	at	first	sexual	intercourse,	individuals	reporting	ages	of	less	than	12	years	were	










	constituent	 ICD-10	 and	 self-reported	 illness	 codes	 for	 derived	 variables,	 is	 shown	 in	
Supplementary	Table	6.2.	All	individuals	with	any	of	the	corresponding	ICD-10	codes	or	self-
reported	illness	codes	for	that	trait	were	considered	cases,	with	all	other	individuals	considered	
controls	 after	 application	 of	 exclusion	 criteria	 (Box	 6.1).	 For	 sex-specific	 conditions,	 only	





















Genotyping	and	 imputation	methods	 for	UK	Biobank	are	described	 in	Chapter	2.	For	all	 traits,	
analyses	were	limited	to	unrelated	individuals	of	white	European	ancestry.	GWAS	for	all	 traits	
was	performed	using	BOLT-LMM	(v2.3)108.	For	disease	traits,	only	those	with	at	least	100	cases	




for	 binary	 traits:	 INFO>0.3	 and	 MAF>0.01	 if	 μ>0.1;	 INFO>0.3	 and	 MAF>0.10	 if	 μ<0.1.	 For	












































with	 acquired	 atrophy	 of	 the	 Fallopian	 tubes	 (rs16938754/G;	OR=28.22,	 P=3.7×10-12),	was	 in	
strong	LD	(r2=0.86,	D’=0.93)	with	a	missense	variant	 in	TMEM70,	 a	mitochondrial	gene	which	
encodes	 a	 protein	 involved	 in	 the	 oxidative	 phosphorylation	 process	 and	 has	 been	 linked	 to	
growth	 retardation	 and	 genital	 malformations	 in	 men263.	 Another	 missense	 variant	
(rs10929757/C)	in	the	oestrogen-responsive	GREB1	gene,	which	has	previously	been	associated	







high	 odds	 ratio	 observed	 here	 may	 reflect	 fine-level	 population	 stratification	 which	 is	
unaccounted	 for	 by	 BOLT-LMM.	 	 Finally,	 two	missense	 variants	 in	 genes	 associated	with	 the	
adaptive	 immune	 response,	 BTAN3A2	 and	 HLA-B,	 were	 also	 implicated	 in	 risk	 for	 prostate	




which	 exist	 for	many	 conditions,	 it	 is	 possible	 that	 BOLT	 is	 still	 not	 adequately	 calibrated	 to	
account	 for	rare	variants	at	 these	extremes.	Therefore,	 the	very	high	odds	ratios	observed	 for	
some	conditions	should	be	interpreted	cautiously.	Recently,	novel	methods	(for	example,
 136 
SAIGE266)	have	been	developed	which	address	case-control	 imbalance	 in	 large	genetic	studies.	















Continuous	Traits	 	 	 	 	 	
Age	when	periods	started	
(menarche)	
237,801	 534	 284	(179)	 27	(6)	 25.16	
Age	first	had	sexual	
intercourse	
392,245	 32	 209	(84)	 181	(63)	 12.86	
Age	at	menopause	(last	
menstrual	cycle)	
142,883	 190	 97	(61)	 19	(1)	 8.41	
Relative	age	of	first	facial	
hair	
200,391	 -	 130	(60)	 130	(60)	 11.02	
Birth	weight	of	first	child	 194,476	 505	 73	(38)	 7	(0)	 8.88	
Relative	age	voice	broke	 191,896	 9	 37	(16)	 32	(12)	 5.49	
Age	at	first	live	birth	 166,894	 19	 48	(13)	 42	(10)	 11.01	
Years	since	last	cervical	
smear	test	
189,529	 -	 10	(4)	 10	(4)	 2.97	
Number	of	live	births	 244,959	 3	 12	(3)	 9	(0)	 6.50	
Age	started	hormone-
replacement	therapy	(HRT)	
86,296	 -	 10	(3)	 10	(3)	 2.98	
Lifetime	number	of	sexual	
partners	
367,437	 118	 17	(2)	 2	(0)	 3.78	
Age	at	last	live	birth	 166,685	 0	 7	(2)	 7	(2)	 6.04	
Age	at	hysterectomy	 455,34	 -	 5	(1)	 5	(1)	 1.72	
Age	started	oral	
contraceptive	pill	
192,635	 -	 4	(1)	 5	(1)	 3.45	
Length	of	menstrual	cycle	 41,774	 7	 4	(1)	 0	(0)	 1.02	
Number	of	children	fathered	 204,950	 -	 1	(1)	 1	(1)	 3.57	
Lifetime	number	of	same-sex	
sexual	partners	
11,723	 -	 9	(0)	 9	(0)	 0.34	
Age	when	last	used	oral	
contraceptive	pill	
175,786	 -	 1	(0)	 1	(0)	 2.26	
Years	since	last	breast	cancer	
screening	/	mammogram	
148,247	 -	 0	(0)	 0	(0)	 0.33	
Time	since	last	menstrual	
period	
48,596	 -	 0	(0)	 0	(0)	 0.27	
Number	of	spontaneous	
miscarriages	
76,281	 -	 0	(0)	 0	(0)	 0.63	
Number	of	pregnancy	
terminations	
76,212	 -	 0	(0)	 0	(0)	 1.93	
Age	of	primiparous	women	
at	birth	of	child	



















16,567	 -	 0	(0)	 0	(0)	 0.57	
Number	of	stillbirths	 76,171	 1	 0	(0)	 (0/0)	 0.16	
	 	 	 		 	 	
Categorical/Binary	Traits	 	 	 	 	 	





392	 35	(22)	 2	(1)	 2.62	
Hyperplasia	of	prostate	 206,951	
(16,479/190,472)	















-	 11	(6)	 11	(6)	 4.75	
Utero-vaginal	prolapse	 245,349	
(7,931/237,418)	
0	 8	(4)	 8	(4)	 2.08	
Malignant	neoplasm	of	testis	 206,951	
(859/206,092)	















-	 6	(3)	 6	(3)	 2.40	
Endometriosis	 245,349	
(7,239/238,110)	
38	 4	(3)	 0	(0)	 1.29	
Hydrocele	and	spermatocele	 206,951	
(1,480/205,471)	




















0	 6	(2)	 6	(2)	 0.00	
Polyp	of	corpus	uteri	 245,349	
(9,691/235,658)	
-	 4	(2)	 4	(2)	 0.66	
Carcinoma	in	situ	of	breast	 245,349	
(2,349/243,000)	











































































































-	 5	(1)	 5	(1)	 0.00	
Vaginal	and	vulva	dysplasia	 245,349	
(368/244,981)	
-	 4	(1)	 4	(1)	 0.09	
Benign	mammary	dysplasia	 245,349	
(3,833/241,516)	





-	 2	(1)	 2	(1)	 0.13	
Enterocele	and	rectocele	 245,349	
(5,040/240,309)	
-	 1	(1)	 1	(1)	 1.17	
Benign	neoplasm	of	breast	 245,349	
(3,212/242,137)	





























































-	 7	(0)	 7	(0)	 0.07	
Puerperal	infections	 208,121	
(251/207,870)	
-	 6	(0)	 6	(0)	 0.00	
Other	obstetric	trauma	 208,121	
(230/207,891)	
-	 6	(0)	 6	(0)	 0.07	
Failed	induction	of	labour	 208,121	
(161/207,960)	











-	 5	(0)	 5	(0)	 0.41	
Polyp	of	vagina	and	vulva	 245,349	
(240/245,109)	





















2	 4	(0)	 4	(0)	 0.00	
Impotence	of	organic	origin	 206,951	
(303/206,648)	






















-	 4	(0)	 4	(0)	 0.20	
Leukoplakia	of	penis	 206,951	
(149/206,802)	





-	 3	(0)	 3	(0)	 0.33	
Placental	disorders	 208,121	
(443/207,678)	

























-	 2	(0)	 2	(0)	 0.11	
Dysplasia	of	cervix	uteri	 245,349	
(2,351/242,998)	





























-	 2	(0)	 2	(0)	 0.14	
Other	disorders	of	breast	 245,349	
(1,315/244,034)	












-	 2	(0)	 2	(0)	 0.25	
Ovulation	bleeding	 245,349	
(1,035/244,314)	





-	 2	(0)	 2	(0)	 0.22	
Balanitis	xerotica	obliterans	 206,951	
(928/206,023)	
-	 2	(0)	 2	(0)	 0.28	
Hypertrophy	of	breast	 245,349	
(697/244,652)	





















18	 2	(0)	 2	(0)	 0.00	
Acne	 452,300	
(399/451,901)	
22	 2	(0)	 2	(0)	 0.28	
Other	obstructed	labour	 208,121	
(411/207,710)	










-	 1	(0)	 1	(0)	 0.39	
Female	infertility	 245,349	
(1,632/243,717)	











-	 1	(0)	 1	(0)	 0.00	
False	labour	 208,121	
(1,152/206,969)	










0	 1	(0)	 1	(0)	 0.12	
Polycystic	ovarian	syndrome	 245,349	
(700/244,649)	





-	 1	(0)	 1	(0)	 0.25	
Ectopic	pregnancy	 208,121	
(641/207,480)	
























-	 1	(0)	 1	(0)	 0.12	
Salpingitis	and	oophritis	 245,349	
(579/244,770)	
















-	 1	(0)	 1	(0)	 0.00	
Multiple	gestation	 208,121	
(292/207,829)	










-	 1	(0)	 1	(0)	 0.00	
Postmenopausal	bleeding	 245,349	
(9,912/235,437)	
-	 0	(0)	 0	(0)	 0.30	
Ovarian	cysts	 245,349	
(8,253/237,096)	










-	 0	(0)	 0	(0)	 0.10	
Poly	of	cervix	uteri	 245,349	
(3,693/241,656)	






-	 0	(0)	 0	(0)	 0.44	
Ever	had	cervical	smear	test	 244,634	
(239,661/4,973)	
-	 0	(0)	 0	(0)	 0.53	
Spontaneous	abortion	 208,121	
(2,695/205,426)	











-	 0	(0)	 0	(0)	 2.27	
Gestational	diabetes	only	 7,112	(863/6,249)	 2	 0	(0)	 0	(0)	 0.13	
Pelvic	peritoneal	adhesions	 245,349	
(2,723/242,626)	





-	 0	(0)	 0	(0)	 0.00	
Single	spontaneous	delivery	 208,121	
(2,211/205,910)	
-	 0	(0)	 0	(0)	 0.00	
Long	labour	 208,121	
(2,089/206,032)	
-	 0	(0)	 0	(0)	 0.35	
Malignant	neoplasm	of	ovary	 245,349	
(1,463/243,886)	



































- 0 (0) 0 (0) 0.06 
Unspecified	lump	in	breast	 245,349 
(1,654/243,695) 
- 0 (0) 0 (0) 0.38 
Postpartum	haemorrhage	 208,121 
(1,414/206,707) 
- 0 (0) 0 (0) 0.56 
Benign	neoplasm	of	ovary	 245,349 
(1,609/243,740) 





0 0 (0) 0 (0) 0.16 
Prolonged	pregnancy	 208,121 
(1,293/206,828) 
- 0 (0) 0 (0) 0.27 
Missed	abortion	 208,121 
(1,261/206,860) 
- 0 (0) 0 (0) 0.00 
Medical	abortion	 208,121 
(1,156/206,965) 
- 0 (0) 0 (0) 0.32 
Endometrial	hyperplasia	 245,349 
(1,219/244,130) 
- 0 (0) 0 (0) 0.00 
Hypertrophy	of	uterus	 245,349 
(1,239/244,110) 





















- 0 (0) 0 (0) 0.06 
Malposition	of	uterus	 245,349 
(835/244,514) 
- 0 (0) 0 (0) 0.00 
HIV	 452,300 
(346/451,954) 










































As	 described	 above,	 one	 advantages	 of	 the	 PheWAS	method	 is	 that	 it	 allows	 identification	 of	
genetic	 variants	which	 have	 potentially	 pleiotropic	 effects.	 Of	 the	 1,966	 independent	 variants	
which	 were	 significantly	 associated	 with	 at	 least	 one	 reproductive	 trait	 at	 a	 genome-wide	
significant	level,	40	were	also	the	lead	variant	for	at	least	one	other	trait.	The	most	pleiotropic	







10)	 in	women	and	with	prostate	hyperplasia	 (OR=1.13,	 P=1.9×10-11)	 in	men.	Other	 variants	 of	
interest	 showed	 associations	 with	 a	 range	 of	 traits,	 including	 associations	 in	 both	 sexes.	
rs34811474/A,	a	missense	variant	within	 the	ANAPC4	 gene	which	 is	 involved	 in	 regulation	of	
mitosis,	was	associated	with	balding	pattern	(β=0.02,	P=4.6×10-11),	age	at	first	sexual	intercourse	
(β=0.05	 years/allele,	 P=5.9×10-9)	 and	 age	 at	 menarche	 (β=0.03	 years/allele,	 P=4.6×10-9).	
Similarly,	a	variant	(rs72709458/T)	mapping	near	the	gene	for	telomerase	reverse	transcriptase	
(TERT)	was	associated	with	increased	risk	of	leiomyoma	of	the	uterus	(OR=1.12,	P=2.9×10-16)	and	


























Years since last cervical smear 
test
Ever used hormone 
replacement therapy
Bilateral oophorectomy

















REPROWAS associations for rs11031005/C
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with	 reproductive	 outcomes.	 A	 total	 of	 95	 genes	 (based	 on	 annotation	 of	 nearest	 gene	 for	




were	 associated	 with	 multiple	 and	 diverse	 reproductive	 traits,	 including	 risk	 of	 bilateral	
oophorectomy	 (rs2235529/T;	 OR=1.12,	 P=2.3×10-14),	 leiomyoma	 of	 uterus	 (rs2235529/T;	
OR=1.15,	 P=3.5×10-19),	 age	 at	 hysterectomy	 (rs3820282/T;	 β=0.45	 years/allele,	 P=7.0×10-11),	
enterocele	 and	 rectocele	 (rs3820282/C;	 OR=0.83,	 P=8.2×10-12),	 offspring	 birth	 weight	
(rs56318008/C;	β=-0.03	kg/allele,	P=9.7×10-9),	uterovaginal	prolapse	(rs61768001/C;	OR=0.85,	
P=2.7×10-13)	 and	 endometriosis	 (rs61768001/C;	 OR=1.17,	 P=7.7×10-12).	 In	 addition,	 an	
approximately	800kB	region	on	chromosome	6	(cytoband	6q25.1-2)	showed	associations	with	12	
different	 reproductive	 traits	 in	 females	 (Figure	 6.3).	 Variants	 at	 this	 locus	 mapped	 to	 three	
different	genes:	SYNE1,	CCDC170	 and	ESR1.	 	The	ESR1	 gene	encodes	oestrogen	receptor	alpha	
(ERα)	 transcription	 factor,	 a	 protein	 which	 is	 activated	 in	 response	 to	 binding	 by	 oestrogen	
promoting	 cell	 proliferation	 and	differentiation.	As	well	 as	 being	 the	primary	 sex	 hormone	 in	
women,	oestrogen	activity	is	essential	for	many	cellular	processes,	and	as	such	ERα	is	expressed	
in	many	different	tissues	throughout	the	body.	eQTL	analysis	using	GTEx	data	was	performed	and	




genetic	 variation	 at	 the	 ESR1	 locus	 has	 been	 implicated	 in	 a	 number	 of	 reproductive	 health	
outcomes	including	timing	of	menarche35	and	menopause245	as	well	as	breast	cancer	risk270.	The	

















































made	 in	 resolving	 the	genetic	architecture	 for	 several	 traits,	genetic	discovery	 for	many	other	
traits	 has	 not	 been	 considered,	 limiting	 our	 insight	 into	 the	 influence	 of	 genetic	 factors	 on	
reproductive	health	as	a	whole.	In	this	chapter,	I	have	described	a	study	to	fill	some	of	these	gaps	



















traits	 in	 this	study	 it	appears	 that	 few	genetic	determinants	of	high	penetrance	may	drive	 the	
genetic	component	of	susceptibility.	This	may	explain	the	preponderance	of	traits	with	very	low	
heritability	estimates	which	still	have	multiple	associated	variants.	For	example,	“absent,	scanty	
or	 rare	menstruation”	 had	 a	 heritability	 estimate	 of	 0.13%	 in	 this	 sample,	 despite	 having	 13	
independent	genome-wide	significant	associated	loci.	Each	of	these	loci	are	rare,	with	MAF<0.03	
and	odds	ratios	ranging	from	12.9	to	97.4.	Rare	mutations	affecting	the	hypothalamic-pituitary-
gonadal	 axis	which	 cause	 delayed	 puberty	 onset	 have	 been	 reported273,	 though	 as	mentioned	
above	the	inflated	ORs	seen	here	may	be	due	to	the	extremely	unbalanced	case-control	ratio	as	
only	120	cases	of	this	condition	were	reported.	More	generally,	this	highlights	a	limitation	of	UK	











widespread	 pleiotropic	 effects	 amongst	 individual	 variants,	 with	 many	 having	 genome-wide	
significant	associations	with	multiple,	and	often	diverse,	reproductive	phenotypes.	This	was	best	
exemplified	 by	 the	 SNP	 rs11031005	 located	 proximal	 to	 the	FSHB	 gene,	 a	 pituitary	 hormone	
which	 along	with	 luteinising	 hormone	 is	 responsible	 for	 stimulating	 gamete	 production.	 This	
variant	 was	 associated	 with	 8	 different	 reproductive	 traits	 with	 seemingly	 diverse	 aetiology,	
including	menstrual	traits,	ovarian	cancer	risk	and	reproductive	timing.	As	mentioned,	FSHB	has	
been	 associated	 with	 accelerated	 reproductive	 ageing,	 and	 has	 been	 identified	 as	 a	 likely	




This	 degree	 of	 pleiotropy	 was	 also	 apparent	 at	 the	 level	 of	 individual	 genes	 as	 well	 as	
chromosomal	regions.	This	is	highlighted	by	the	ESR1/SYNE1/CCDC170	locus	on	chromosome	6,	
where	multiple	variants	within	this	region	were	independently	associated	with	different	aspects	







This	 study	 design	 has	 several	 key	 advantages	 compared	 to	 other	 similar	 efforts	 to	 conduct	
PheWAS	 in	 large	 cohort	 studies.	 Cortes	 et	 al.	 recently	 described	 a	method	 to	 interrogate	 the	
















conditions	we	 are	 only	 powered	 to	 detect	 variants	 of	 large	 effect,	which	 can	 bias	 heritability	
estimates	downward	and	risks	missing	some	of	the	common	variation	which	may	drive	more	mild	
cases	of	disease.	Similarly,	because	UK	Biobank	is	an	older	cohort	focused	on	studying	diseases	of	


















knowledge	on	 the	 genetic	 determinants	 of	 reproductive	health	 and	disease.	 Combining	GWAS	
summary	results	across	multiple,	expertly	curated	reproductive	phenotypes	reveals	many	novel	
variant-trait	associations	for	conditions	which	have	previously	been	understudied,	and	provides	



























































































































timing	 associated	 variants	 for	 hundreds	 of	 reproductive	 outcomes	 in	 the	REPROWAS	data,	 to	
identify	 associations	between	puberty	 timing	and	general	 reproductive	health.	 I	 then	perform	
univariate	and	multivariate	MR	analyses	using	the	newly	generated	sex	hormone	GWAS	data,	in	
combination	with	previously	published	data	on	BMI-related	variants,	to	investigate	the	extent	to	































An	alternative	 theory	has	been	proposed	that	sex	hormones	may	be	 the	primary	driver	of	 the	
associations	 between	 puberty	 timing	 and	 disease	 risk.	 Sex	 steroid	 hormones	 are	 the	 primary	
regulators	of	reproductive	function,	and	their	increased	production	in	pre-pubertal	children	is	an	
essential	part	of	the	initiation	of	puberty	and	the	development	of	secondary	sexual	characteristics.	








hormone	 exposure	 in	 individuals	 who	 go	 through	 puberty	 earlier	 may	 explain	 some	 of	 the	
reported	adverse	health	associations281–283.	This	is	supported	by	observed	associations	between	
sex	 hormone	 levels	 and	 disease	 risk	 for	 several	 reproductive	 conditions.	 For	 example,	 higher	
testosterone	 levels	 are	 observed	 in	 women	 with	 polycystic	 ovary	 syndrome	 (PCOS)284,	 and	
testosterone	has	been	positively	associated	with	increased	risk	of	cardiovascular	disease,	obesity	
and	 T2D285–287.	 Sex	 hormones	 are	 also	 known	 to	 promote	 growth	 and	 metastasis	 of	 certain	




































identifying	 associations	 is	 only	 the	 first	 step	 towards	 truly	 understanding	 the	 aetiological	
mechanisms	which	relate	earlier	sexual	maturation	to	unfavourable	health	consequences	later	in	
life.	 Inferring	casual	associations	using	Mendelian	randomisation	analyses	has	 the	potential	 to	
increase	our	understanding	of	 this	 important	 subject.	 In	 the	previous	 chapter,	 I	described	 the	









and	 endogenous	 sex	 hormone	 exposure,	 mediate	 any	 identified	 associations	 between	
puberty	timing	and	reproductive	traits;	and	













































a	 panel	 of	 34	 biomarkers	were	 produced	 from	blood	 and	 urine	 samples	 collected	 at	 baseline	
assessment	 (see	 Chapter	 2).	 These	 included	 three	 traits	 pertaining	 to	 sex	 hormones:	 SHBG,	
testosterone	and	oestradiol.	These	three	phenotypes	were	used	in	the	analysis	described	in	this	
chapter.	A	fourth	phenotype,	which	derived	the	amount	of	bioactive	testosterone	(Free-T)	based	
on	 a	 previously	 validated	method301	was	 also	 included	 in	 the	 analysis.	 Genetic	 discovery	was	
limited	to	individuals	of	white	European	ancestry,	identified	based	on	self-reported	ancestry	from	
online	questionnaires	and	 the	 first	 four	genetically	determined	principle	components.	 In	 total,	
425,097	participants	who	had	phenotype	and	genotype	data	which	passed	QC	measures	were	
included	 in	 the	 analyses.	 Association	 testing	 was	 performed	 using	 linear	 mixed	 models	




at	 or	 below	 the	 lower	 limit	 of	 detection	 versus	 all	 others.	 All	 other	 traits	 were	 modelled	 as	
continuous	variables	based	on	measured	concentrations	of	the	hormone.	Each	model	included	age	
at	 baseline,	 genotyping	 chip	 and	 the	 first	 10	 genetically	 determined	 principle	 components	 as	









Independent	 variants	were	 identified	 by	 distance-based	 clumping	 of	 genome-wide	 significant	
variants	(P<5.0×10-8),	where	the	variant	with	the	lowest	P-value	within	1MB	was	considered	the	









as	 the	 strong	genetic	 correlation	between	male	and	 female	puberty	 timing35,	 the	389	variants	
identified	in	the	most	recent	GWAS	for	AAM	were	used	as	the	primary	instrument	for	puberty	
timing	 in	 this	analysis.	These	were	applied	 to	both	male	and	 female	 reproductive	 traits.	Two-
sample	 inverse	 variance	 weighted	 (IVW)	 MR	 analyses	 were	 performed	 for	 each	 of	 the	 181	
reproductive	 traits,	 using	 the	 AAM	 instrument	 as	 the	 exposure	 and	 the	 corresponding	 effect	
estimates	 from	 REPROWAS	 summary	 statistics	 as	 the	 outcome	 measure.	 Analyses	 were	
implemented	using	the	‘TwoSampleMR’	package	in	R.	For	all	nominally	significant	associations	
identified	by	this	method	(P<0.05),	further	IVW	MR	analyses	were	conducted	using	instruments	
for	 BMI	 and	 the	 sex	 hormone	 phenotypes.	 For	 BMI,	 this	 comprised	 the	 96	 bi-allelic	 variants	
identified	 in	 the	 European	 sex-combined	 sample	 from	 the	 most	 recently	 published	 genetic	
discovery	 by	 the	 GIANT	 consortium155.	 For	 the	 sex	 hormone	 phenotypes,	 instruments	 were	














To	 further	 investigate	 the	 extent	 to	 which	 BMI	 and	 sex	 hormones	 mediate	 the	 associations	
between	 puberty	 timing	 and	 reproductive	 health	 outcomes,	 multivariate	 MR	 analyses	 were	




































































Exposure	 Study	 GWAS	signals	 Included	in	instrument	for	exposure#	
AAM	 Day	et	al.35	 389	 358	
Voice	breaking	 Hollis	et	al.	(Chapter	3)	 76	 76	
BMI	 Locke	et	al.155	 97	 96	
Total-T	 Ruth	et	al.	(unpublished)	 	 	
Men	 	 231	 221	
Women	 	 254	 248	
Free-T	 Ruth	et	al.	(unpublished)	 	 	
Men	 	 125	 106	
Women	 	 180	 176	
SHBG	 Ruth	et	al.	(unpublished)	 	 	
Men	 	 357	 342	
Women	 	 359	 351	












(26	 female-specific,	 8	male-specific	 and	2	 shared;	Supplementary	Tables	7.1	and	7.2).	After	
correcting	 for	 the	 number	 of	 tests,	 this	 resulted	 in	 12	 significant	 associations	 in	 females	


























non-significant	 for	all	 traits,	however	this	 is	 likely	due	to	the	 low	statistical	power	of	 this	 test.	
Conversely	weighted	median	MR	analyses,	which	relies	on	different	assumptions	to	MR-Egger	and	
is	 generally	 better	 powered	 to	 detect	 associations,	 were	 nominally	 significant	 for	 all	 traits	
(P<0.05).	Furthermore,	none	of	the	traits	showed	evidence	of	horizontal	pleiotropy	(MR-Egger	
intercept	 P-value	 >0.05)	 with	 the	 exception	 of	 AAM	 (Pintercept=1.9×10-5).	 Pleiotropy	 would	 be	
expected	in	this	instance	given	that	known	AAM	variants	were	used	to	generate	the	instrument	
for	 exposure,	 and	 the	 trait	 was	 included	 as	 an	 outcome	 here	 merely	 as	 a	 positive	 control.	












BMI	 was	 negatively	 associated	 with	 6	 of	 the	 9	 puberty-associated	 continuous	 phenotypes	 in	
women	with	at	least	nominal	significance	(Figure	7.1	(a)	and	Supplementary	Table	7.1).	The	
inverse	 relationship	 with	 these	 traits	 is	 consistent	 with	 the	 observation	 that	 higher	 BMI	 is	
associated	with	earlier	onset	of	puberty.	In	contrast,	among	binary	traits	BMI	was	only	associated	
with	 risk	 of	 leiomyoma	 of	 the	 uterus	 with	 nominal	 significance,	 where	 higher	 genetically	
predicted	BMI	showed	evidence	of	increasing	the	risk	for	this	trait	(OR=1.13,	95%CI=1.01-1.27).	






Several	 continuous	 reproductive	 traits	 in	 women	 showed	 evidence	 of	 associations	 with	
testosterone	and	SHBG.	A	higher	genetically	predicted	level	of	Total-T	was	significantly	associated	
(P<4.2×10-3,	 =0.05/12	 tests)	with	 earlier	 sexual	 debut	 (AFS	β=-0.09,	 95%CI=-0.15-	 -0.03)	 and	
fewer	 years	 since	 last	 cervical	 smear	 test	 (β=-0.17,	 95%CI=-0.28-	 -0.05)	 (Figure	 7.1	 (a)	 and	
Supplementary	Table	7.1).	When	 considering	bioactive	 testosterone	 (Free-T),	AFS	 remained	
significantly	associated	(β=-0.26,	95%CI=-0.35	-	-0.18)	while	negative	associations	were	observed	
with	 additional	 traits	 related	 to	 reproductive	 ageing	 and	 behaviour	 including	 	 AAM	 (β=-0.11,	
95%CI=-0.19	–	0.04)	and	ages	at	first		(β=-0.37,	95%CI=-0.52	-	-0.23)	and	last	(β=-0.23,	95%CI=-
0.36	-	-0.09)	live	birth.	SHBG	showed	only	one	significant	association,	where	higher	genetically	




Higher	 Total-T	 showed	 evidence	 of	 having	 a	 protective	 effect	 for	 leiomyoma	 of	 the	 uterus	
(OR=0.88,	 95%CI=0.82-0.94)	 as	 well	 as	 a	 suggestive	 protective	 effect	 for	 risk	 of	 bilateral	
oophorectomy	(OR=0.93,	95%CI=0.86-0.99).	Bioactive	testosterone	showed	null	effects	for	both	
traits	(Figure	7.1	(b)	and	Supplementary	Table	7.2).	Higher	genetically	predicted	SHBG	also	
demonstrated	 significantly	 protective	 effects	 for	 both	 traits	 (OR=0.78,	 95%CI=0.71-0.85	 for	
leiomyoma	and	OR=0.85,	95%CI=0.78-0.93	for	bilateral	oophorectomy).	As	no	association	was	






































































factors	 in	 the	 association	 between	 puberty	 timing	 and	 reproductive	 health	 outcomes.	 Among	

































































	 Unadjusted	 Adj.	BMI	 Adj.	Testosterone	 Adj.		Free-T	 Adj.		SHBG	
Trait	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	 Beta	(SE)	 P-value	
Female	Continuous	Traits	




















































































































































AAM	 compared	 to	 voice	 breaking	 and	 strong	 genetic	 correlation	 (rg=0.74)	 between	 these	
phenotypes35.	However,	this	has	the	potential	to	miss	any	sex-specific	effects	of	puberty	variants	
in	men,	which	may	have	differential	effects	that	are	not	adequately	captured	by	an	instrument	
composed	solely	of	AAM	variants.	We	 therefore	 repeated	 the	 IVW	MR	analyses	across	all	181	




with	 reproductive	 outcomes	 (Supplementary	 Table	 7.3).	 Of	 the	 37	 traits	 which	 showed	
nominally	significant	associations	with	puberty	based	on	the	AAM-derived	instrument,	15	also	
showed	nominally	significant	associations	when	the	voice	breaking	instrument	was	used.	All	15	
traits	 were	 directionally	 concordant	 with	 the	 AAM	 instrument.	 In	 addition,	 a	 further	 11	
associations	were	identified	which	showed	null	association	with	the	AAM	instrument.	Of	these,	8	





MR	 analyses	 using	 the	 instrumental	 exposures	 for	 Total-T,	 Free-T	 and	 SHBG	 for	 all	 the	 traits	




breastfeeding).	 The	 effect	 in	 breast	 cancer	 was	 slightly	 higher	 when	 considering	 biologically	
active	 testosterone	 (Free-T;	OR=1.23,	95%CI=1.11-1.37)	but	 showed	null	 effects	on	 the	 ‘other	
disorders	 of	 the	 breast’	 phenotype	 (OR=1.23,	 95%CI=0.95-1.61).	Higher	 SHBG	was	 associated	
with	 increased	 risk	 for	 both	 false	 labour	 (commonly	 known	 as	 Braxton	 Hicks	 contractions;	
OR=1.72,	95%CI=1.36-2.36)	and	carcinomas	of	the	cervix	(OR=1.61,	95%CI=1.15-2.27).	Neither	










































relative	 importance	 of	 two	 of	 the	 hypothesised	 potential	mediating	mechanisms,	 BMI-related	
effects	 and	 increased	 endogenous	 sex-hormone	 exposure,	 is	 unknown	 for	many	 traits.	Here,	 I	

















with	 both	 relatively	 earlier	 and	 relatively	 later	 puberty	 onset	 associated	 with	 earlier	 age	 at	
menarche128,245,	an	association	that	would	not	be	captured	with	the	current	study	design.	Of	more	
interest	 were	 the	 three	 associations	 with	 disease	 traits:	 leiomyoma	 of	 the	 uterus,	 bilateral	
oophorectomy	and	cystitis/UTI.	Both	leiomyomas	and	oophorectomies	have	been	associated	with	
earlier	puberty39,	but	this	is	the	first	time	to	our	knowledge	that	either	has	been	assessed	using	




















outcomes	 in	 women	 have	 naturally	 focused	 on	 oestrogen	 exposure	 given	 that	 this	 is	 the	
predominant	mediator	of	sexual	function	in	women.	Thus,	the	influence	of	androgens	on	female	
reproductive	 traits	 remains	 understudied.	 Here,	 we	 observed	 that	 Free-T	 appeared	 to	 be	 a	












Free-T	 and	 Total-T	 predicted	 lower	 AFS	 in	 women,	 suggesting	 a	 more	 general	 effect	 of	 sex	
hormones	on	sexual	behaviours.	Interestingly,	in	men	we	observed	a	nominally	significant	effect	
of	Total-T	on	AFS	which	was	directionally	opposite	to	the	effect	in	women,	whereby	higher	Total-






Earlier	 AAM	 was	 associated	 with	 increased	 risk	 for	 leiomyomas	 of	 the	 uterus,	 bilateral	
oophorectomy	and	cystitis/UTI.	Leiomyomas	have	previously	been	associated	with	both	BMI	and	
endogenous	 sex	 hormones	 including	 androgens	 and	 oestrogens306,307.	 Here	 we	 demonstrate	
evidence	for	a	nominally	significant	casual	effect	of	higher	BMI	on	increased	uterine	leiomyoma	
risk	which	 is	directionally	 consistent	with	previous	 studies.	With	 regard	 to	 sex	hormones,	we	




goes	back	 to	1996	and	 incident	cases	may	have	been	diagnosed	previous	 to	 this.	For	bilateral	
oophorectomies,	no	association	was	found	with	BMI	while	significant	inverse	associations	were	
observed	for	both	Total-T	and	SHBG.	Androgen	levels	have	been	associated	with	ovarian	cancer,	
however	oestrogens	are	a	stronger	predictor	of	risk308.	 It	has	 thus	been	hypothesised	 that	 the	
association	may	be	due,	at	 least	 in	part,	 to	the	 fact	 that	 testosterone	 is	an	 intermediate	on	the	
























Related	 to	 this	 point,	 the	 molecular	 pathways	 and	 intermediates	 products	 of	 sex	 hormone	
synthesis	is	complex,	and	while	capturing	the	effects	of	the	key	endpoints	of	these	pathways	is	a	
valuable	 starting	 point	 a	 more	 in-depth	 picture	 will	 likely	 be	 gained	 in	 future	 studies	 by	
considering	a	broader	spectrum	of	sex	hormones	and	their	intermediates.	Finally,	while	this	study	
aimed	 to	 shed	 light	 on	 the	 relative	 importance	 of	 BMI	 and	 sex	 hormones	 as	 explanatory	









while	 implicates	 both	 of	 these	 as	 potential	 mediators	 of	 the	 associations.	 Identifying	 the	
mechanisms	which	 link	puberty	 to	 later	 life	 health	 is	 an	 important	 part	 of	 understanding	 the	














































































































both	 of	 these	 traits	 have	 often	 been	 considered	 in	 both	 genetic	 and	 observational	 studies,	
important	questions	remain	regarding	the	aetiological	pathways	through	which	they	exert	their	
effects	on	health.	In	this	concluding	chapter	I	summarise	the	findings	of	this	thesis,	putting	them	



























































specific	 genetic	 discovery	has	 been	 advocated,	 and	 examples	 of	 sexual	 dimorphism	of	 genetic	
effects	for	many	traits	have	been	reported311–313.	This	is	of	heightened	importance	in	the	field	of	














idea	 of	 phenotypic	 plasticity	 during	 critical	 windows	 of	 development	 in	 response	 to	
environmental	 triggers.	While	a	contribution	of	 inherited	 factors	 is	not	 incompatible	with	 this	
concept,	the	potential	for	the	pleiotropic	effects	of	genes	which	influence	both	birth	weight	and	
the	 health	 outcome	 of	 interest	 must	 be	 taken	 into	 account	 when	 examining	 potential	
developmental	 causes35,314,315.	 	 In	Chapter	4	 I	used	multivariate	MR	analyses	 to	demonstrate	a	
causal	effect	of	maternal	genetically-predicted	birth	weight	on	body	fat	distribution	in	offspring.	
This	 approach	 theoretically	 reduces	 the	 probability	 that	 pleiotropic	 effects	 of	 the	 genes	 are	
influencing	 the	 results,	 as	 adjusting	 for	 the	 foetal	 effects	 implies	 that	 the	 maternal	 effects	
represent	the	developmental	environment.	The	effects	observed	are	in	line	with	predictions	of	the	
DOHaD	hypothesis,	with	lower	genetically-predicted	birth	weight	conferring	increased	central	fat	
deposition	 and	 decreased	 peripheral	 fat	 –	 a	 metabolically	 unhealthy	 distribution	 which	 may	
explain	the	associations	with	poor	cardio-metabolic	health.	This	does	not	necessarily	imply	that	















5	 I	 re-analysed	existing	data	as	well	 as	employing	a	novel	method	 to	 impute	methylation	and	







casual	 loci	 identified.	 Of	 particular	 interest	 were	 the	 9	 loci	 which	 had	 not	 previously	 been	
identified	in	GWAS	for	puberty	timing,	which	indicates	that	these	loci	are	only	associated	with	this	






In	 Chapter	 6	 I	 described	 a	 PheWAS	 study	 conducted	 for	 all	 reproductive	 health	 traits	 in	 UK	
Biobank,	 which	 were	 expertly	 curated	 to	 maximise	 sample	 size	 and	 preserve	 specificity	 of	
aetiology	for	each	trait.	This	revealed	evidence	of	widespread	pleiotropy,	with	many	SNPs,	genes	





































that	 study	 participants	 were	 generally	 healthier	 and	 from	 better	 socioeconomic	 positions.	 In	
addition,	participants	were	more	likely	to	be	older,	female	and	less	likely	to	be	smokers	or	heavy	
drinkers321.	Similarly	for	the	23andMe	cohort,	participants	are	self-selected	based	on	their	ability	
and	 willingness	 to	 pay	 for	 personalised	 genetic	 testing.	 This	 is	 also	 likely	 to	 lead	 to	 a	 non-










consideration	 in	 this	 thesis	 is	 that	 the	UK	Biobank	cohort,	on	which	many	of	 the	chapters	are	
based,	was	designed	to	capture	the	diseases	of	middle	and	older-age.	Therefore	using	this	cohort	


























to	 test	 for	 the	 possibility	 of	 pleiotropy	 and	 the	 heterogeneous	 effects	 of	 SNPs	 influencing	 the	
conclusions.	 However,	 these	 methods	 are	 not	 able	 to	 fully	 mitigate	 the	 potential	 of	 reverse	
causality.	While	 bi-directional	MRs	 can	 provide	 evidence	 for	 or	 against	 a	 causal	 effect	 in	 the	

























clinical	 and	 public	 health	 benefits.	 After	 years	 of	 relatively	 slow	 progress,	 the	 potential	 of	
population-based	genetic	studies	to	transform	clinical	practice	is	beginning	to	be	realised.	
	
The	 utility	 of	 genetic	 data	 in	 clinical	 and	 public	 health	 settings	 are	 in	 two	 principle	 areas:	 1)	
identifying	targets	for	pharmaceutical	intervention	(i.e.	drug	discovery);	and	2)	risk	stratification	





reduction	 strategies.	 Such	 an	 approach	 can	 easily	 be	 envisaged	 for	 puberty	 timing,	 where	
interventions	to	reduce	obesity	 in	childhood	could	be	 implemented.	Similarly	 for	birth	weight,	
identifying	 mothers	 and	 children	 who	 are	 genetically	 predisposed	 to	 lower	 birth	 weight	 can	
inform	pre-	 and	post-natal	 care	 to	 reduce	 the	potential	 for	downstream	health	 consequences.	
Identifying	which	individuals	should	be	targeted,	and	when,	must	be	carefully	considered.	Given	
the	 importance	 of	 early	 life	 exposures	 in	 determining	 health	 outcomes,	 the	 earlier	 genetic	
information	can	be	obtained	the	better	the	chances	for	successful	intervention.	While	higher	risk	
individuals	may	be	identified	based	on	factors	including	clinical	indicators,	socio-demographics	
and	 family	history,	 in	 the	 future	 routine	genetic	 screening	may	bring	 the	benefits	of	precision	
medicine	to	all	individuals.		
	







to	 date	 is	 the	 lack	 of	 ethnic	 diversity	 in	 discovery	 samples.	 It	 has	 been	 suggested	 that	 this	











on	 general	 and	 reproductive	 health.	 The	 results	 provide	 evidence	 of	 the	 importance	 of	
developmental	 processes	 in	 influencing	 health	 throughout	 the	 life	 course,	 which	 may	 have	



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Endocytosis	 9	 -	 242	 3.50E-04	 -	 1	
Cell	cycle	 6	 -	 123	 1.20E-03	 -	 1	
Hedgehog	signaling	pathway	 4	 -	 46	 1.60E-03	 -	 1	
Insulin	signaling	pathway	 6	 -	 134	 1.60E-03	 -	 1	
Neomycin,	kanamycin	and	gentamicin	
biosynthesis	
2	 -	 5	 3.60E-03	 -	 1	
B	cell	receptor	signaling	pathway	 4	 -	 71	 5.30E-03	 -	 1	
Aldosterone-regulated	sodium	reabsorption	 3	 -	 37	 7.20E-03	 -	 1	
Carbohydrate	digestion	and	absorption	 3	 -	 42	 9.80E-03	 -	 1	
Endocrine	and	other	factor-regulated	calcium	
reabsorption	
3	 -	 47	 1.26E-02	 -	 1	
Viral	myocarditis	 3	 -	 56	 1.92E-02	 -	 1	
Antigen	processing	and	presentation	 3	 -	 66	 2.75E-02	 -	 1	
Phagosome	 4	 -	 145	 3.95E-02	 -	 1	
Non-alcoholic	fatty	liver	disease	(NAFLD)	 4	 -	 149	 4.26E-02	 -	 1	
Oxytocin	signaling	pathway	 4	 -	 149	 4.26E-02	 -	 1	
Galactose	metabolism	 2	 -	 31	 4.48E-02	 -	 1	
Fc	gamma	R-mediated	phagocytosis	 3	 -	 89	 4.77E-02	 -	 1	
Fructose	and	mannose	metabolism	 2	 -	 33	 4.77E-02	 -	 1	
Starch	and	sucrose	metabolism	 2	 -	 33	 4.77E-02	 -	 1	
Allograft	rejection	 2	 -	 35	 4.99E-02	 -	 1	
Cortisol	synthesis	and	secretion	 6	 -	 63	 -	 3.20E-04	 2	
Long-term	depression	 5	 -	 60	 -	 1.70E-03	 2	
Chagas	disease	(American	trypanosomiasis)	 6	 -	 101	 -	 1.80E-03	 2	
















Th17	cell	differentiation	 6	 -	 102	 -	 1.90E-03	 2	
TNF	signaling	pathway	 6	 -	 108	 -	 2.10E-03	 2	
Leukocyte	transendothelial	migration	 6	 -	 112	 -	 2.40E-03	 2	
Cocaine	addiction	 4	 -	 49	 -	 4.40E-03	 2	
Aldosterone	synthesis	and	secretion	 5	 -	 93	 -	 5.50E-03	 2	
Phosphatidylinositol	signaling	system	 5	 -	 97	 -	 6.10E-03	 2	
Melanogenesis	 5	 -	 98	 -	 6.20E-03	 2	
Glucagon	signaling	pathway	 5	 -	 100	 -	 6.40E-03	 2	
Toll-like	receptor	signaling	pathway	 5	 -	 102	 -	 6.80E-03	 2	
Inflammatory	bowel	disease	(IBD)	 4	 -	 62	 -	 7.50E-03	 2	
Antifolate	resistance	 3	 -	 31	 -	 9.00E-03	 2	
Leishmaniasis	 4	 -	 70	 -	 1.02E-02	 2	
Sphingolipid	signaling	pathway	 5	 -	 116	 -	 1.02E-02	 2	
Vascular	smooth	muscle	contraction	 5	 -	 119	 -	 1.08E-02	 2	
Thyroid	hormone	synthesis	 4	 -	 73	 -	 1.10E-02	 2	
Graft-versus-host	disease	 3	 -	 36	 -	 1.15E-02	 2	
Calcium	signaling	pathway	 6	 -	 179	 -	 1.20E-02	 2	
Natural	killer	cell	mediated	cytotoxicity	 5	 -	 124	 -	 1.20E-02	 2	
RNA	degradation	 4	 -	 77	 -	 1.20E-02	 2	
Thyroid	cancer	 3	 -	 37	 -	 1.20E-02	 2	
Dopaminergic	synapse	 5	 -	 128	 -	 1.27E-02	 2	
Hepatitis	C	 5	 -	 131	 -	 1.38E-02	 2	
Fluid	shear	stress	and	atherosclerosis	 5	 -	 133	 -	 1.45E-02	 2	
















Th1	and	Th2	cell	differentiation	 4	 -	 88	 -	 1.67E-02	 2	
Morphine	addiction	 4	 -	 91	 -	 1.77E-02	 2	
Amoebiasis	 4	 -	 94	 -	 1.93E-02	 2	
Pancreatic	secretion	 4	 -	 95	 -	 1.98E-02	 2	
NOD-like	receptor	signaling	pathway	 5	 -	 166	 -	 2.89E-02	 2	
Serotonergic	synapse	 4	 -	 112	 -	 3.20E-02	 2	
Tuberculosis	 5	 -	 172	 -	 3.20E-02	 2	
Purine	metabolism	 5	 -	 173	 -	 3.23E-02	 2	
Oocyte	meiosis	 4	 -	 116	 -	 3.48E-02	 2	
Renin-angiotensin	system	 2	 -	 23	 -	 3.52E-02	 2	
Amphetamine	addiction	 3	 -	 65	 -	 3.63E-02	 2	
Herpes	simplex	infection	 5	 -	 181	 -	 3.67E-02	 2	
Epithelial	cell	signaling	in	Helicobacter	pylori	
infection	
3	 -	 66	 -	 3.70E-02	 2	
Renal	cell	carcinoma	 3	 -	 68	 -	 3.92E-02	 2	
Bile	secretion	 3	 -	 71	 -	 4.34E-02	 2	
Inositol	phosphate	metabolism	 3	 -	 73	 -	 4.57E-02	 2	
Hippo	signaling	pathway	-	multiple	species	 2	 -	 28	 -	 4.60E-02	 2	
Pertussis	 3	 -	 74	 -	 4.65E-02	 2	
Pathways	in	cancer	 19	 22	 515	 3.06E-07	 1.26E-07	 Both	
Endocrine	resistance	 9	 8	 95	 2.37E-06	 5.98E-05	 Both	
FoxO	signaling	pathway	 10	 9	 130	 2.37E-06	 5.98E-05	 Both	
Breast	cancer	 10	 10	 147	 3.64E-06	 3.11E-05	 Both	


















7	 5	 61	 9.11E-06	 1.70E-03	 Both	
Prostate	cancer	 8	 7	 97	 1.13E-05	 3.30E-04	 Both	
Signaling	pathways	regulating	pluripotency	of	
stem	cells	
9	 8	 138	 1.17E-05	 3.50E-04	 Both	
Glioma	 7	 7	 68	 1.20E-05	 6.10E-05	 Both	
PI3K-Akt	signaling	pathway	 13	 9	 348	 1.23E-05	 9.20E-03	 Both	
Melanoma	 7	 7	 72	 1.40E-05	 7.88E-05	 Both	
Rap1	signaling	pathway	 10	 11	 203	 2.05E-05	 5.98E-05	 Both	
Longevity	regulating	pathway	 7	 7	 88	 4.15E-05	 2.20E-04	 Both	
Viral	carcinogenesis	 9	 7	 183	 6.18E-05	 4.60E-03	 Both	
HIF-1	signaling	pathway	 7	 7	 98	 7.02E-05	 3.30E-04	 Both	
mTOR	signaling	pathway	 8	 6	 148	 9.73E-05	 6.40E-03	 Both	
Prolactin	signaling	pathway	 6	 6	 69	 1.00E-04	 3.70E-04	 Both	
Cellular	senescence	 8	 11	 156	 1.20E-04	 1.01E-05	 Both	
Type	II	diabetes	mellitus	 5	 3	 46	 2.00E-04	 1.74E-02	 Both	
Estrogen	signaling	pathway	 7	 6	 133	 3.50E-04	 4.60E-03	 Both	
Maturity	onset	diabetes	of	the	young	 4	 3	 26	 3.60E-04	 6.40E-03	 Both	
Small	cell	lung	cancer	 6	 4	 92	 3.60E-04	 1.82E-02	 Both	
Epstein-Barr	virus	infection	 8	 6	 194	 4.20E-04	 1.54E-02	 Both	
Human	papillomavirus	infection	 10	 10	 317	 4.20E-04	 2.20E-03	 Both	
AGE-RAGE	signaling	pathway	in	diabetic	
complications	
6	 10	 98	 4.40E-04	 2.27E-06	 Both	
Non-small	cell	lung	cancer	 5	 4	 66	 7.00E-04	 9.00E-03	 Both	
Hepatocellular	carcinoma	 7	 9	 163	 8.40E-04	 2.20E-04	 Both	
















AMPK	signaling	pathway	 6	 5	 120	 1.10E-03	 1.10E-02	 Both	
Chronic	myeloid	leukemia	 5	 4	 76	 1.10E-03	 1.20E-02	 Both	
Kaposi's	sarcoma-associated	herpesvirus	
infection	
7	 9	 183	 1.40E-03	 3.60E-04	 Both	
Relaxin	signaling	pathway	 6	 6	 130	 1.50E-03	 4.40E-03	 Both	
HTLV-I	infection	 8	 9	 250	 1.60E-03	 1.90E-03	 Both	
Measles	 6	 5	 133	 1.60E-03	 1.45E-02	 Both	
Focal	adhesion	 7	 7	 197	 1.80E-03	 6.10E-03	 Both	
Ovarian	steroidogenesis	 4	 5	 49	 1.90E-03	 7.40E-04	 Both	
Progesterone-mediated	oocyte	maturation	 5	 5	 94	 2.20E-03	 5.70E-03	 Both	
MicroRNAs	in	cancer	 6	 7	 149	 2.40E-03	 1.90E-03	 Both	
Regulation	of	lipolysis	in	adipocytes	 4	 4	 53	 2.40E-03	 5.50E-03	 Both	
cGMP-PKG	signaling	pathway	 6	 7	 160	 3.30E-03	 2.50E-03	 Both	
Insulin	resistance	 5	 6	 107	 3.50E-03	 2.10E-03	 Both	
Ras	signaling	pathway	 7	 7	 228	 3.60E-03	 1.03E-02	 Both	
Central	carbon	metabolism	in	cancer	 4	 5	 65	 4.30E-03	 1.90E-03	 Both	
Acute	myeloid	leukemia	 4	 4	 66	 4.40E-03	 9.00E-03	 Both	
Neurotrophin	signaling	pathway	 5	 4	 116	 4.40E-03	 3.48E-02	 Both	
Thyroid	hormone	signaling	pathway	 5	 6	 115	 4.40E-03	 2.60E-03	 Both	
p53	signaling	pathway	 4	 6	 68	 4.60E-03	 3.60E-04	 Both	
Adherens	junction	 4	 3	 71	 5.30E-03	 4.34E-02	 Both	
Osteoclast	differentiation	 5	 5	 124	 5.30E-03	 1.20E-02	 Both	
Platelet	activation	 5	 5	 123	 5.30E-03	 1.18E-02	 Both	
Pancreatic	cancer	 4	 5	 74	 5.70E-03	 2.60E-03	 Both	
















EGFR	tyrosine	kinase	inhibitor	resistance	 4	 6	 78	 6.70E-03	 6.50E-04	 Both	
Phospholipase	D	signaling	pathway	 5	 6	 145	 9.40E-03	 6.10E-03	 Both	
Gastric	cancer	 5	 7	 147	 9.80E-03	 1.90E-03	 Both	
Cushing's	syndrome	 5	 8	 153	 1.12E-02	 5.70E-04	 Both	
Influenza	A	 5	 6	 168	 1.60E-02	 1.02E-02	 Both	
Transcriptional	misregulation	in	cancer	 5	 11	 169	 1.61E-02	 1.62E-05	 Both	
Cholinergic	synapse	 4	 4	 111	 1.92E-02	 3.14E-02	 Both	
Endometrial	cancer	 3	 5	 58	 2.04E-02	 1.50E-03	 Both	
VEGF	signaling	pathway	 3	 3	 59	 2.10E-02	 3.05E-02	 Both	
Basal	cell	carcinoma	 3	 4	 63	 2.47E-02	 7.80E-03	 Both	
Fc	epsilon	RI	signaling	pathway	 3	 3	 67	 2.82E-02	 3.81E-02	 Both	
Apelin	signaling	pathway	 4	 5	 133	 3.18E-02	 1.45E-02	 Both	
Gastric	acid	secretion	 3	 4	 72	 3.31E-02	 1.08E-02	 Both	
Adrenergic	signaling	in	cardiomyocytes	 4	 6	 139	 3.58E-02	 5.50E-03	 Both	
Alcoholism	 4	 5	 142	 3.79E-02	 1.70E-02	 Both	
Hepatitis	B	 4	 7	 142	 3.79E-02	 1.80E-03	 Both	
Hippo	signaling	pathway	 4	 5	 152	 4.43E-02	 2.10E-02	 Both	
Insulin	secretion	 3	 5	 84	 4.44E-02	 4.20E-03	 Both	
Colorectal	cancer	 3	 5	 85	 4.48E-02	 4.30E-03	 Both	
Gap	junction	 3	 4	 87	 4.69E-02	 1.62E-02	 Both	
Dilated	cardiomyopathy	(DCM)	 3	 4	 88	 4.77E-02	 1.67E-02	 Both	
GnRH	signaling	pathway	 3	 4	 88	 4.77E-02	 1.67E-02	 Both	
Jak-STAT	signaling	pathway	 4	 5	 160	 4.77E-02	 2.54E-02	 Both	
Inflammatory	mediator	regulation	of	TRP	
channels	
3	 8	 92	 4.99E-02	 5.98E-05	 Both	
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cg00094412	 6:	29592854	 GABBR1	 rs2747429	 6:	29648377	 55523	 1.38E-74	 -0.0187	 1.01E-05	
cg00108715	 3:	52565015	 NT5DC2	 rs6778735	 3:	52565100	 85	 8.60E-28	 0.0151	 9.42E-07	
cg00138407	 3:	47386505	 KLHL18	 rs295458	 3:	47385585	 -920	 2.52E-14	 -0.0037	 1.60E-01	
cg00238353	 10:	129785537	 PTPRE	 rs61873722	 10:	129789935	 4398	 1.34E-29	 0.0006	 9.12E-01	
cg00244001	 10:	126336805	 FAM53B	 rs11245333	 10:	126383088	 46283	 6.60E-17	 0.0013	 5.87E-01	
cg00431050	 10:	103985730	 ELOVL3	 rs61873698	 10:	104207431	 221701	 3.32E-19	 -0.0173	 1.54E-02	
cg00673344	 3:	156807691	 LINC00880	 rs3113	 3:	156814949	 7258	 4.54E-30	 0.0036	 3.57E-01	
cg00863378	 16:	56549757	 BBS2	 rs72814488	 16:	56498493	 -51264	 2.04E-236	 -0.0089	 3.34E-02	
cg00973118	 16:	374570	 AXIN1	 rs3848365	 16:	374617	 47	 2.81E-223	 -0.0011	 7.70E-01	
cg01243823	 16:	50732212	 NOD2	 rs6500328	 16:	50736656	 4444	 5.78E-30	 0.0034	 1.99E-01	
cg01511901	 13:	31004719	 UBE2L5P	 rs1028937	 13:	30945840	 -58879	 5.22E-11	 -0.001	 7.14E-01	
cg02286155	 5:	176826262	 SLC34A1	 rs7708314	 5:	176809618	 -16644	 2.07E-09	 0.0042	 2.88E-01	
cg02650017	 17:	47301614	 PHOSPHO1	 rs850523	 17:	47313931	 12317	 4.31E-14	 -0.0075	 5.08E-02	
cg02716826	 9:	33447032	 AQP3	 rs591810	 9:	33447424	 392	 1.59E-15	 0.0029	 3.35E-01	
cg03050965	 1:	101705237	 S1PR1	 rs6680048	 1:	101620370	 -84867	 9.28E-09	 -0.0041	 1.91E-01	
cg03159676	 16:	85600536	 GSE1	 rs9921154	 16:	85597734	 -2802	 2.81E-31	 0.0032	 3.85E-01	
cg03433986	 11:	62477624	 BSCL2	 rs516580	 11:	62492124	 14500	 1.79E-12	 0.0049	 1.09E-01	
cg03523676	 14:	24540235	 CPNE6	 rs7146599	 14:	24527672	 -12563	 5.90E-73	 0.0101	 6.38E-03	
cg03725309	 1:	109757585	 SARS	 rs4970829	 1:	109757295	 -290	 4.32E-08	 -0.0082	 2.47E-01	
cg03885055	 1:	16723232	 SPATA21	 rs149561	 1:	16797485	 74253	 6.51E-06	 -0.0051	 1.76E-01	
cg04011474	 2:	28904455	 RNA5SP89	 rs55720575	 2:	28889033	 -15422	 1.91E-14	 0.0064	 7.84E-02	
cg04126866	 10:	85932763	 C10orf99	 rs68097915	 10:	85937538	 4775	 3.42E-30	 -0.0005	 8.88E-01	
cg04232128	 5:	138861241	 TMEM173	 rs9716069	 5:	138842818	 -18423	 8.56E-15	 -0.0056	 7.15E-02	
cg04577162	 7:	73667397	 RFC2	 rs3135660	 7:	73664710	 -2687	 2.19E-33	 0.0093	 1.79E-01	
cg05063895	 16:	2073518	 SLC9A3R2	 rs28698483	 16:	2080571	 7053	 5.07E-06	 0.0117	 2.51E-03	
cg05720226	 7:	116786597	 ST7	 rs10270156	 7:	116789934	 3337	 4.02E-230	 -0.0003	 9.50E-01	
cg05845030	 12:	91573247	 DCN	 rs2639662	 12:	91683609	 110362	 8.22E-10	 0	 9.99E-01	
cg06012428	 6:	157477204	 ARID1B	 rs74854649	 6:	157373244	 -103960	 1.11E-06	 0.0013	 8.44E-01	
cg06192883	 15:	52554171	 MYO5C	 rs71472932	 15:	52541976	 -12195	 2.43E-05	 -0.0119	 4.19E-02	
cg06559575	 12:	53490352	 IGFBP6	 rs10876407	 12:	53502438	 12086	 1.43E-30	 -0.0125	 5.28E-04	
cg06898549	 12:	41083590	 CNTN1	 rs4768288	 12:	40922091	 -161499	 3.95E-12	 -0.0032	 3.43E-01	
cg07021906	 16:	87866833	 SLC7A5	 rs4262954	 16:	87814595	 -52238	 1.39E-18	 0.004	 2.86E-01	
cg07037944	 15:	64290807	 DAPK2	 rs28660107	 15:	64281243	 -9564	 5.05E-05	 0.007	 1.29E-01	
cg07136133	 11:	36422377	 PRR5L	 rs59943655	 11:	36422532	 155	 1.04E-20	 -0.008	 2.12E-01	
cg07471614	 8:	125855152	 LINC00964	 rs11777682	 8:	125860396	 5244	 2.62E-12	 -0.0004	 9.12E-01	
cg07504977	 10:	102131012	 LINC00263	 rs145744215	 10:	102129774	 -1238	 6.60E-49	 0.001	 8.39E-01	
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cg07682160	 19:	18959935	 UPF1	 rs7250622	 19:	18984843	 24908	 1.41E-06	 -0.0116	 2.10E-03	
cg07728579	 15:	83475013	 FSD2	 rs12594415	 15:	83527562	 52549	 1.25E-26	 0.0017	 6.75E-01	
cg07769588	 19:	10655622	 ATG4D	 rs62128793	 19:	10642931	 -12691	 1.85E-10	 0.0003	 9.50E-01	
cg08305942	 16:	79692354	 MAF	 rs4889009	 16:	79700447	 8093	 1.03E-27	 -0.0003	 9.08E-01	
cg08309687	 21:	35320596	 LINC00649	 rs8128167	 21:	35307200	 -13396	 1.92E-68	 -0.0038	 1.54E-01	
cg08443038	 16:	89006877	 CBFA2T3	 rs491224	 16:	88995480	 -11397	 9.73E-30	 0.0079	 3.42E-02	
cg08548559	 22:	31686097	 PIK3IP1	 rs739427	 22:	31659101	 -26996	 3.27E-310	 0.0049	 5.77E-02	
cg08726900	 16:	89550474	 ANKRD11	 rs2019604	 16:	89615765	 65291	 8.48E-06	 0.0081	 1.35E-02	
cg08857797	 17:	40927699	 VPS25	 rs55999482	 17:	40919453	 -8246	 2.39E-07	 0.002	 6.26E-01	
cg09152259	 2:	128156114	 MAP3K2	 rs2276683	 2:	128146762	 -9352	 3.27E-310	 0.0009	 8.37E-01	
cg09554443	 1:	167487762	 CD247	 rs58946921	 1:	167506299	 18537	 5.65E-14	 0.0035	 5.19E-01	
cg09664445	 17:	2612406	 CLUH	 rs12051903	 17:	2555511	 -56895	 4.55E-11	 0.0011	 7.78E-01	
cg09777883	 11:	112093696	 BCO2	 rs67245191	 11:	112072161	 -21535	 1.43E-106	 0.0079	 4.23E-02	
cg10179300	 5:	14147618	 TRIO	 rs352657	 5:	14170410	 22792	 2.18E-45	 -0.0046	 2.12E-01	
cg10438589	 4:	14531493	 LINC00504	 rs16890352	 4:	14385522	 -145971	 2.64E-31	 0.0127	 3.96E-02	
cg10513161	 3:	183705727	 ABCC5	 rs6773408	 3:	183716609	 10882	 6.93E-68	 0.0031	 3.99E-01	
cg10717869	 1:	205780912	 SLC41A1	 rs4396169	 1:	205768309	 -12603	 3.74E-12	 0.0065	 1.21E-02	
cg10919522	 14:	74227441	 ELMSAN1	 rs11624967	 14:	74227246	 -195	 1.95E-40	 0.0041	 1.20E-01	
cg10922280	 16:	68034227	 DUS2L	 rs8059305	 16:	68036666	 2439	 1.77E-21	 0.0048	 1.61E-01	
cg10927968	 11:	1807333	 CTSD	 rs55877559	 11:	1778176	 -29157	 1.07E-04	 -0.0041	 5.27E-01	
cg11024682	 17:	17730094	 SREBF1	 rs8070432	 17:	17480474	 -249620	 4.83E-19	 -0.0034	 5.35E-01	
cg11080651	 5:	10445523	 ROPN1L	 rs62364292	 5:	10445835	 312	 6.10E-06	 -0.0128	 8.15E-02	
cg11202345	 17:	76976057	 LGALS3BP	 rs8071100	 17:	76783078	 -192979	 4.25E-12	 0.005	 2.94E-01	
cg11376147	 11:	57261198	 SLC43A1	 rs2511984	 11:	57278733	 17535	 1.76E-07	 -0.0052	 2.11E-01	
cg11614585	 20:	897050	 ANGPT4	 rs1014898	 20:	895531	 -1519	 3.34E-12	 0.0045	 2.93E-01	
cg11650298	 13:	44690989	 SMIM2-AS1	 rs10507524	 13:	44684600	 -6389	 3.43E-07	 0.0018	 6.77E-01	
cg11832534	 1:	3563998	 WRAP73	 rs3765706	 1:	3597224	 33226	 7.32E-35	 -0.0005	 9.07E-01	
cg11927233	 5:	170816542	 NPM1	 rs78276384	 5:	170815521	 -1021	 9.48E-15	 0.0092	 6.73E-02	
cg12593793	 1:	156074135	 LMNA	 rs915179	 1:	156078249	 4114	 2.69E-18	 0.0061	 2.22E-02	
cg12992827	 3:	101901234	 ZPLD1	 rs13087130	 3:	101901067	 -167	 3.48E-73	 0.0015	 6.01E-01	
cg13591783	 9:	75768868	 ANXA1	 rs2795112	 9:	75769950	 1082	 5.65E-37	 -0.0011	 7.82E-01	
cg13781414	 9:	138951648	 NACC2	 rs4842069	 9:	138891645	 -60003	 5.51E-07	 -0.0021	 5.94E-01	
cg13922488	 19:	14545201	 PKN1	 rs3826758	 19:	14572497	 27296	 2.95E-06	 -0.0061	 1.07E-01	
cg14020176	 17:	72764985	 SLC9A3R1	 rs12601504	 17:	72754829	 -10156	 2.02E-41	 0.003	 2.77E-01	
cg14264316	 9:	134280803	 PRRC2B	 rs34159422	 9:	134386659	 105856	 7.11E-07	 0.0068	 2.74E-01	
cg14476101	 1:	120255992	 PHGDH	 rs11583993	 1:	120255370	 -622	 3.85E-228	 0.0109	 7.48E-02	
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cg15323828	 1:	226053673	 TMEM63A	 rs9919303	 1:	226044766	 -8907	 3.50E-216	 0.0048	 1.22E-01	
cg15681239	 3:	38080203	 DLEC1	 rs4389435	 3:	38080101	 -102	 1.54E-219	 0.0008	 7.82E-01	
cg16163382	 2:	37938640	 CDC42EP3	 rs9808547	 2:	37944134	 5494	 5.45E-16	 -0.0058	 4.11E-02	
cg16578636	 10:	92987457	 PCGF5	 rs2648718	 10:	93011770	 24313	 1.10E-33	 0.0077	 9.80E-03	
cg16594806	 1:	59473943	 PHBP3	 rs2716121	 1:	59474554	 611	 2.44E-144	 -0.0003	 9.00E-01	
cg16815882	 1:	35908609	 KIAA0319L	 rs1188633	 1:	35903912	 -4697	 4.51E-09	 -0.0047	 3.11E-01	
cg16846518	 3:	128062608	 EEFSEC	 rs2687729	 3:	127895226	 -167382	 1.51E-11	 0.0056	 5.55E-02	
cg17260706	 11:	118782879	 BCL9L	 rs523604	 11:	118755738	 -27141	 8.69E-05	 0.0018	 5.04E-01	
cg17501210	 6:	166970252	 RPS6KA2	 rs9355572	 6:	166732650	 -237602	 1.09E-08	 -0.0016	 7.08E-01	
cg17901584	 1:	55353706	 DHCR24	 rs687565	 1:	55364663	 10957	 6.22E-33	 0.0064	 8.61E-02	
cg17971578	 1:	36852463	 STK40	 rs72663467	 1:	36837953	 -14510	 1.29E-09	 -0.0093	 9.52E-02	
cg18098839	 3:	167742700	 GOLIM4	 rs73174980	 3:	167747239	 4539	 4.97E-45	 0.0111	 1.25E-01	
cg18120259	 6:	43894639	 C6orf223	 rs7745517	 6:	43895095	 456	 1.12E-173	 0.0074	 8.98E-02	
cg18181703	 17:	76354621	 SOCS3	 rs62080378	 17:	76282256	 -72365	 1.34E-05	 -0.0029	 4.30E-01	
cg18219562	 17:	41773643	 MEOX1	 rs1107747	 17:	41774270	 627	 1.43E-05	 -0.0052	 5.29E-02	
cg18513344	 3:	195531298	 MUC4	 rs2688530	 3:	195535466	 4168	 2.03E-62	 0.0021	 6.40E-01	
cg19217955	 17:	7123994	 ACADVL	 rs62062765	 17:	6894691	 -229303	 1.70E-05	 0.0022	 7.48E-01	
cg19373099	 2:	210008092	 CRYGFP	 rs6707503	 2:	210068146	 60054	 3.56E-27	 0.0035	 3.59E-01	
cg19566658	 7:	100466241	 TRIP6	 rs13306969	 7:	100525805	 59564	 1.12E-124	 -0.0029	 3.90E-01	
cg19589396	 8:	103937374	 RPL5P24	 rs613049	 8:	103931309	 -6065	 1.80E-67	 0.0018	 5.08E-01	
cg21108085	 11:	44591098	 CD82	 rs10769059	 11:	44590729	 -369	 7.46E-06	 0.0008	 8.31E-01	
cg21429551	 7:	30635762	 GARS	 rs3779250	 7:	30694260	 58498	 2.89E-13	 0.0001	 9.85E-01	
cg21486834	 17:	74477542	 RHBDF2	 rs3826288	 17:	74477340	 -202	 5.63E-30	 0.0066	 1.66E-01	
cg22012981	 3:	58522689	 ACOX2	 rs4681863	 3:	58521124	 -1565	 3.85E-26	 -0.0045	 4.19E-01	
cg22103219	 7:	101934892	 SH2B2	 rs803092	 7:	101932722	 -2170	 1.35E-47	 0.0026	 4.77E-01	
cg22488164	 12:	14716910	 PLBD1	 rs746690	 12:	14783798	 66888	 1.93E-17	 -0.0048	 9.00E-02	
cg22534374	 1:	201511610	 RPS10P7	 rs11582434	 1:	201507911	 -3699	 1.91E-266	 0.0026	 4.76E-01	
cg23032421	 3:	3152038	 IL5RA	 rs168025	 3:	3150530	 -1508	 2.65E-21	 -0.0005	 8.88E-01	
cg23232188	 3:	121556543	 EAF2	 rs9854539	 3:	121503395	 -53148	 8.09E-30	 0.0061	 2.22E-02	
cg24403644	 20:	42574624	 TOX2	 rs4812770	 20:	42575630	 1006	 2.53E-15	 -0.0053	 2.52E-01	
cg24469729	 7:	27160520	 HOXA-AS2	 rs3807592	 7:	27136729	 -23791	 4.22E-135	 0.0036	 2.15E-01	
cg24679890	 19:	17246356	 MYO9B	 rs111366154	 19:	17309577	 63221	 7.20E-13	 0.0164	 3.44E-02	
cg25001190	 1:	61668835	 NFIA	 rs78378256	 1:	61662952	 -5883	 1.94E-17	 0	 9.95E-01	
cg25197194	 3:	128758787	 EFCC1	 rs2341295	 3:	128751102	 -7685	 2.72E-54	 0.004	 1.32E-01	
cg25217710	 1:	156609523	 BCAN	 rs6666910	 1:	156566111	 -43412	 4.46E-06	 0.0006	 8.82E-01	
cg25435714	 7:	157083381	 RN7SL142P	 rs2527874	 7:	157073637	 -9744	 7.38E-49	 0.0048	 3.25E-01	
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cg25570328	 2:	108903952	 SULT1C2	 rs2305484	 2:	108905030	 1078	 1.29E-07	 0.0001	 9.79E-01	
cg25649826	 17:	20938740	 USP22	 rs7226229	 17:	20924077	 -14663	 3.34E-127	 0.0045	 1.59E-01	
cg26033520	 10:	74004071	 ANAPC16	 rs4746108	 10:	74016892	 12821	 3.59E-12	 -0.0022	 4.28E-01	
cg26253134	 2:	70751721	 TGFA	 rs72912111	 2:	70773571	 21850	 1.83E-12	 -0.0083	 1.40E-01	
cg26357885	 14:	65006204	 HSPA2	 rs45526332	 14:	65006583	 379	 2.70E-24	 -0.0129	 7.40E-02	
cg26361535	 8:	144576604	 ZC3H3	 rs7844860	 8:	144636949	 60345	 1.95E-44	 0.003	 4.12E-01	
cg26403843	 5:	158634085	 RNF145	 rs6556405	 5:	158635102	 1017	 3.27E-310	 0.0066	 3.95E-02	
cg26542660	 4:	56813860	 CEP135	 rs878956	 4:	56814115	 255	 1.04E-19	 -0.0026	 4.92E-01	
cg26663590	 16:	28959310	 NFATC2IP	 rs115616784	 16:	29000446	 41136	 4.75E-69	 0.0197	 2.36E-07	
cg26687842	 13:	41055491	 LINC00598	 rs2721069	 13:	41143720	 88229	 1.34E-10	 0.0047	 9.99E-02	
cg26804423	 7:	8201134	 ICA1	 rs10085429	 7:	8209069	 7935	 5.06E-44	 -0.0012	 7.32E-01	
cg26878209	 10:	112375475	 SMC3	 rs11195232	 10:	112375282	 -193	 3.70E-42	 -0.0027	 4.13E-01	
cg26894079	 11:	122954435	 CLMP	 rs34817879	 11:	123023729	 69294	 2.95E-06	 0.0009	 8.47E-01	
cg26952928	 8:	142230233	 SLC45A4	 rs3824235	 8:	142222261	 -7972	 7.92E-34	 0.0045	 2.27E-01	
cg27050612	 17:	46133198	 NFE2L1	 rs2325750	 17:	46022330	 -110868	 2.26E-06	 -0.0052	 6.64E-02	
cg27087650	 19:	45255796	 BCL3	 rs62117162	 19:	45239536	 -16260	 7.81E-21	 0.0023	 7.25E-01	
cg27115863	 22:	37921640	 CARD10	 rs6000762	 22:	37918472	 -3168	 1.01E-09	 0.0014	 6.69E-01	
cg27117792	 12:	102330180	 DRAM1	 rs12298720	 12:	102318856	 -11324	 6.23E-12	 0.0024	 5.62E-01	
cg27184903	 15:	29285727	 APBA2	 rs11852567	 15:	29292973	 7246	 1.49E-41	 0.0064	 2.83E-01	
cg27547344	 1:	43765617	 TIE1	 rs3120124	 1:	43764165	 -1452	 7.96E-91	 0.0014	 7.16E-01	













































































Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	
Hyperplasia	of	prostate	 15,530	 8,974	 N40	 Enlarged	prostate;	BPH/benign	prostatic	
hypertrophy	
"Cystitis	&	other	urinary	tract	infections"	 20,910	 3,083	 N30.0,	N30.1,	N30.2,	N30.3,	N30.4,	
N30.8,	N30.9,	N39.0	 Urinary	tract	infection/kidney	infection;	cystitis	







Malignant	neoplasm	of	prostate	 9,013	 4,159	 C61	
Prostate	cancer	
	





11,746	 -	 N92.0	 -	







"Ovarian	cysts"	 6,188	 4,347	 N83.0,	N83.1,	N83.2	
Ovarian	cyst	or	cysts	
	
Uterovaginal	prolapse	 6,721	 3,038	 N81.2,	N81.3,	N81.4	
Vaginal	prolapse/uterine	prolapse	
	
Perineal	laceration	during	delivery	 7,643	 -	 O70.0,	O70.1,	O70.2,	O70.3,	O70.9	
-	
	
"Enterocele	&	Rectocele"	 6,205	 -	 N81.5,	N81.6	
-	
	





















Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	




3,424	 -	 N92.1	 -	









Female	pelvic	peritoneal	adhesions	 3,278	 -	 N73.6	 -	
	




2,272	 550	 N95.1,	N95.2,	N95.3,	N95.8,	N95.9	 Menopausal	symptoms/menopause	
Carcinoma	in	situ	of	breast	 2,807	 -	 D05.0,	D05.1,	D05.7,	D05.9	 -	
	












2,549	 -	 N47	 -	
Long	labour	 2,539	 -	 O63.0,	O63.1,	O63.9	 -	
	
Malignant	neoplasm	of	ovary	 1,593	 904	 C56	 Ovarian	cancer	
	









"Dysmenorrhoea"	 1,947	 378	 N94.4,	N94.5,	N94.6	 Dysmenorrhoea	
	




Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	
Other	noninflammatory	disorders	of	vulva	
and	perineum	
2,106	 -	 N90.5,	N90.6,	N90.7,	N90.8,	N90.9	 -	




Female	infertility	 1,438	 627	 N97.0,	N97.1,	N97.2,	N97.3,	N97.4,	
N97.8,	N97.9	
Female	infertility	
Unspecified	lump	in	breast	 1,952	 -	 N63	 -	
	
Malignant	neoplasm	of	corpus	uteri	 1,918	 -	 C54.0,	C54.1,	C54.2,	C54.3,	C54.8,	
C54.9,	C55	
-	
Postpartum	haemorrhage	 1,778	 -	 O72.0,	O72.1,	O72.2,	O72.3	 -	
	
Benign	neoplasm	of	ovary	 1,769	 -	 D27	 -	
	
Other	disorders	of	prostate	 1,730	 -	 N42.0,	N42.1,	N42.2,	N42.3,	N42.8,	
N42.9	
-	
Hydrocele	and	spermatocele	 1,702	 -	 N43.0,	N43.1,	N43.2,	N43.3,	N43.4	 -	
	




1,639	 -	 O34.2	 -	
Prolonged	pregnancy	 1,569	 -	 O48	 -	
	
Other	disorders	of	breast	 1,558	 -	 N64.0,	N64.1,	N64.2,	N64.3,	N64.4,	
N64.5,	N64.8,	N64.9	
-	
Missed	abortion	 1,546	 -	 O02.1	 -	
	








"Endometrial	hyperplasia"	 1,483	 -	 N85.0,	N85.1	 -	
	




Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	
False	labour	 1,421	 -	 O47.0,	O47.1,	O47.9	 -	
	




1,393	 -	 N94.8,	N94.9,	N94.0,	N94.2,	N94.3	 -	
Malignant	neoplasm	of	testis	 387	 921	 C62.0,	C62.1,	C62.9	 Testicular	cancer	
	
Erosion	and	ectropion	of	cervix	uteri	 1,145	 120	 N86	 Cervical	erosion	
	












1,181	 -	 O99.0	 -	
"Gestational	hypertension	&	Eclampsia"	 1,172	 -	 O13,	O14.0,	O14.1,	O14.9,	O15.0,	O15.1,	
O15.2,	O15.9	
-	
Ovulation	bleeding	 1,171	 -	 N92.3	 -	
	
Carcinoma	in	situ	of	cervix	uteri	 723	 411	 D06.0,	D06.1,	D06.7,	D06.9	 Cervical	intra-epithelial	neoplasia	(cin)/pre-
cancerous	cells	(cervix)	
Balanitis	xerotica	obliterans	 1,041	 -	 N48.6	 -	
	
Hypertrophy	of	breast	 1,017	 -	 N62	 -	
	
Other	inflammation	of	vagina	and	vulva	 988	 -	 N76.0,	N76.1,	N76.2,	N76.3,	N76.4,	
N76.5,	N76.6,	N76.8	
-	
Polycystic	ovarian	syndrome	 300	 660	 E28.2	 Polycystic	ovaries/polycystic	ovarian	syndrome	
	
"Cyst	or	abscess	of	Bartholin's	gland"	 960	 -	 N75.0,	N75.1	 -	
	













Ectopic	pregnancy	 384	 493	 O00.1,	O00.2,	O00.8,	O00.9	 Ectopic	pregnancy	
	
Unspecified	maternal	hypertension	 853	 -	 O16	 -	
	







Vascular	disorders	of	male	genital	organs	 774	 -	 N50.1	 -	
	
Single	delivery	by	Caesarean	section	 755	 -	 O82.0,	O82.1,	O82.8,	O82.9	 -	
	














628	 -	 N83.8	 -	
Inflammatory	disorders	of	breast	 613	 -	 N61	 -	
	
Abnormalities	of	forces	of	labour	 601	 -	 O62.0,	O62.1,	O62.2,	O62.3,	O62.4,	
O62.8,	O62.9	
-	











Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	
Other	specified	disorders	of	penis	 543	 -	 N48.8	 -	
	
Other	female	genital	prolapse	 527	 -	 N81.8	 -	
	
"Undescended	testicle	&	Hypospadias"	 270	 227	 Q53.0,	Q53.1,	Q53.2,	Q53.9,	Q54.0,	
Q54.1,	Q54.4,	Q54.8,	Q54.9	
Undescended	testicle	
Acne	 83	 401	 L70.0,	L70.8,	L70.9	 Acne/acne	vulgaris	
	









Other	benign	neoplasms	of	uterus	 455	 -	 D26.0,	D26.1,	D26.7,	D26.9	 -	
	








Multiple	gestation	 390	 -	 O30.0,	O30.1,	O30.2,	O30.8	 -	
	
Malignant	neoplasm	of	cervix	uteri	 388	 -	 C53.0,	C53.1,	C53.8,	C53.9	 -	
	
Excessive	vomiting	in	pregnancy	 382	 -	 O21.0,	O21.1,	O21.2,	O21.8,	O21.9	 -	
	
Impotence	of	organic	origin	 376	 -	 N48.4	 -	
	













370	 -	 N92.4	 -	
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Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	








361	 -	 D07.5	 -	










333	 -	 O75.6	 -	
"Testicular	hypofunction	&	Male	
Infertility"	
292	 36	 E29.1,	N64	 Male	infertility	
	
Balanoposthitis	 328	 -	 N48.1	 -	
	















Fistulae	involving	female	genital	tract	 282	 -	 N82.0	,	N82.1	,	N82.2	,	N82.3	,	N82.4	,	
N82.5	,	N82.8	,	N82.9	
-	






270	 -	 N77.1	 -	




256	 -	 D28.0	,	D28.1	,	D28.2	,	D28.7	,	D28.9	 -	
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Maternal	care	for	excessive	foetal	growth	 231	 -	 O36.6	 -	
	











211	 -	 O75.7	 -	
"Gestational	oedema	&	proteinuria"	 195	 -	 O12.0	,	O12.1	,	O12.2	 -	
	
Oligohydramnios	 193	 -	 O41.0	 -	
	
Maternal	care	for	tumour	of	corpus	uteri	 186	 -	 O34.1	 -	
	





184	 -	 O75.2	 -	
"Neoplasm	of	uncertain	or	unknown	
behaviour,	ovary"	
183	 -	 D39.1	 -	




Leukoplakia	of	penis	 172	 -	 N48.0	 -	
	





169	 -	 O99.6	 -	
Polyhydramnios	 162	 -	 O40	 -	
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Phenotype	 							Cases	(N)								 																				Constituent	variables																					ICD-10	 Self-reports	 ICD-10	codes	 Self-reported	illness	codes	
"Other	disorders	of	amniotic	fluid	and	
membranes"	
152	 -	 O41.1,	O41.8,	O41.9	 -	
















140	 -	 N83.3	 -	
	




138	 -	 D48.6	 -	




122	 -	 O10.0,	O10.1,	O10.2,	O10.9	 -	
Venous	complications	in	the	puerperium	 120	 -	 O87.0,	O87.1,	O87.2,	O87.8,	O87.9	 -	
Maternal	care	for	abnormality	of	vulva	and	
perineum	
119	 -	 O34.7	 -	
Malignant	neoplasm	of	other	and	
unspecified	female	genital	organs	




113	 -	 O99.2	 -	






105	 -	 O99.3	 -	

























































































































































































































































































































































































































































































































































































































































































Supplementary	 Figure	 6.1:	 Hierarchical	 structure	 of	 ICD-10	 coded	 diagnoses	 for	 disease	
categorisation.	Example	for	ectopic	pregnancies,	showing	four	levels	of	increasing	specificity.	
	
	
	
	
	
Supplementary	Figure	6.2:	Self-reported	illness	classifications	in	UK	Biobank	Data	Showcase.	
Example	showing	polycystic	ovarian	syndrome.
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